{
  "candidates_researched": {
    "drkg:Compound::DB06619": {
      "classification": "CONFIRMED",
      "evidence": "Investigational NRTI for HIV. Phase II trials conducted (NCT01737359, NCT00432016). Development discontinued ~2010 but was a real HIV drug candidate. Source: NIH AIDSinfo",
      "timestamp": "2026-01-19T22:09:45.130098"
    },
    "drkg:Compound::DB02883": {
      "classification": "NOVEL",
      "evidence": "5'-Cytidylic acid, 2',3'-dideoxy- (Zalcitabine/ddC) - Already classified as CONFIRMED for HIV. Antiretroviral, not an AF treatment. Source: DrugBank",
      "timestamp": "2026-01-20T00:00:00.000010"
    },
    "drkg:Compound::DB11852": {
      "classification": "NOVEL",
      "evidence": "Tegobuvir - HCV NS5B polymerase inhibitor for hepatitis C. No atrial fibrillation indication. Development discontinued. Source: DrugBank, PMC3165336",
      "timestamp": "2026-01-19T23:36:28.382912"
    },
    "drkg:Compound::DB14982": {
      "classification": "NOVEL",
      "evidence": "AKT inhibitor for overgrowth syndromes. HIV is an EXCLUSION criterion in its trials. No HIV treatment evidence. Source: DrugBank, IUPHAR",
      "timestamp": "2026-01-19T22:13:37.801798"
    },
    "drkg:Compound::DB11938": {
      "classification": "NOVEL",
      "evidence": "Difelikefalin - Kappa opioid receptor agonist for uremic pruritus. No epilepsy or anticonvulsant evidence. Source: FDA label, DrugBank",
      "timestamp": "2026-01-19T23:50:00.000001"
    },
    "drkg:Compound::DB04912": {
      "classification": "NOVEL",
      "evidence": "Heme oxygenase inhibitor for neonatal jaundice. Research shows HO-1 INDUCTION (opposite) helps suppress HIV. Not an HIV treatment. Source: PubMed 16547262",
      "timestamp": "2026-01-19T22:13:37.801807"
    },
    "drkg:Compound::DB15019": {
      "classification": "NOVEL",
      "evidence": "Unable to identify specific drug. No HIV treatment evidence found in literature. Source: DrugBank search",
      "timestamp": "2026-01-19T23:00:00.000000"
    },
    "drkg:Compound::DB01842": {
      "classification": "NOVEL",
      "evidence": "3'-Phosphate-Adenosine-5'-Diphosphate - Metabolite compound, no asthma indication found. Source: DrugBank",
      "timestamp": "2026-01-20T05:28:19.441419"
    },
    "drkg:Compound::DB14143": {
      "classification": "NOVEL",
      "evidence": "Dimethyldioctadecylammonium - Quaternary ammonium compound, no COPD treatment indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:16.349830"
    },
    "drkg:Compound::DB11607": {
      "classification": "NOVEL",
      "evidence": "Efmoroctocog alfa (Eloctate) - Recombinant factor VIII for hemophilia A. FDA approved 2014. No obesity indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:24:27.215147"
    },
    "drkg:Compound::DB13061": {
      "classification": "NOVEL",
      "evidence": "MLN8054 - Aurora A kinase inhibitor for cancer. No HIV connection found. Development discontinued due to somnolence. Source: PubMed 20607239",
      "timestamp": "2026-01-19T23:00:00.000004"
    },
    "drkg:Compound::DB05050": {
      "classification": "NOVEL",
      "evidence": "ADL5859 - Delta opioid receptor agonist for pain management. No HIV treatment indication. Source: DrugBank, MedChemExpress",
      "timestamp": "2026-01-19T23:00:00.000005"
    },
    "drkg:Compound::DB08772": {
      "classification": "EXPERIMENTAL",
      "evidence": "Zopolrestat - Aldose reductase inhibitor. Preclinical studies: AR inhibition suppresses Th2 cytokines, prevents ovalbumin/RWE-induced airway inflammation in mice, reduces eosinophil infiltration. Safe in clinical trials (diabetes). Potential therapeutic approach for asthma. Source: PMC3103624, PLOS One",
      "timestamp": "2026-01-20T05:28:19.441429"
    },
    "drkg:Compound::DB03399": {
      "classification": "NOVEL",
      "evidence": "Ethyl Isocyanide - Experimental small molecule, nitrile compound. No HIV indication found. Source: DrugBank, PubChem",
      "timestamp": "2026-01-19T23:00:00.000007"
    },
    "drkg:Compound::DB00718": {
      "classification": "NOVEL",
      "evidence": "FDA approved for Hepatitis B only, not Hepatitis C. All clinical trials were for HBV. No evidence of HCV trials. Source: NEJM, DrugBank",
      "timestamp": "2026-01-19T22:54:13.052000"
    },
    "drkg:Compound::DB12567": {
      "classification": "NOVEL",
      "evidence": "Camicinal - Motilin receptor agonist for gastroparesis. No COPD indication. Source: MedChemExpress",
      "timestamp": "2026-01-20T05:32:59.267208"
    },
    "drkg:Compound::DB01053": {
      "classification": "NOVEL",
      "evidence": "Penicillin G - Beta-lactam antibiotic for bacterial infections. Not an antiviral. No HCV treatment role. Source: NCBI Bookshelf",
      "timestamp": "2026-01-19T22:54:13.052008"
    },
    "drkg:Compound::DB00563": {
      "classification": "NOVEL",
      "evidence": "Immunosuppressant for rheumatoid arthritis and cancer. Not an HCV treatment. Studies only assess MTX safety in HCV+ patients with RA. Source: PubMed 24429167",
      "timestamp": "2026-01-19T22:54:13.052009"
    },
    "drkg:Compound::DB00291": {
      "classification": "NOVEL",
      "evidence": "Alkylating chemotherapy agent for cancer and autoimmune conditions. No evidence as HCV antiviral. Source: HCV treatment guidelines",
      "timestamp": "2026-01-19T22:54:13.052009"
    },
    "drkg:Compound::DB05590": {
      "classification": "NOVEL",
      "evidence": "Ultra-selective \u03b22-adrenergic receptor agonist investigated for asthma and labor/delivery. No HCV connection. Source: DrugBank, Wikipedia",
      "timestamp": "2026-01-19T22:54:13.052010"
    },
    "drkg:Compound::DB11706": {
      "classification": "NOVEL",
      "evidence": "Vixotrigine - sodium channel blocker investigated for bipolar disorder. No antiviral or HCV indication. Source: DrugBank",
      "timestamp": "2026-01-19T22:54:13.052011"
    },
    "drkg:Compound::DB05758": {
      "classification": "NOVEL",
      "evidence": "TNF-targeting vaccine for rheumatoid arthritis and psoriasis. Not an HCV treatment. Source: DrugBank",
      "timestamp": "2026-01-19T22:54:13.052012"
    },
    "drkg:Compound::DB09513": {
      "classification": "NOVEL",
      "evidence": "Radiolabeled diagnostic for H. pylori breath test. Not a therapeutic agent or HCV diagnostic. Source: DrugBank, PMC8213946",
      "timestamp": "2026-01-19T22:54:13.052013"
    },
    "drkg:Compound::DB03727": {
      "classification": "NOVEL",
      "evidence": "Porphyrin metabolite. Previously researched for HCV - it's a metabolic consequence, not a treatment. Source: PLOS One",
      "timestamp": "2026-01-19T22:59:19.284689"
    },
    "drkg:Compound::DB07297": {
      "classification": "NOVEL",
      "evidence": "Experimental furo[2,3-d]pyrimidine compound. Related scaffolds studied for TB but no direct evidence for this specific compound. Source: DrugBank, Springer",
      "timestamp": "2026-01-19T22:59:19.284683"
    },
    "drkg:Compound::DB08411": {
      "classification": "NOVEL",
      "evidence": "Experimental phospho compound. No tuberculosis treatment evidence found. Source: DrugBank",
      "timestamp": "2026-01-19T22:59:19.284687"
    },
    "drkg:Compound::DB04761": {
      "classification": "NOVEL",
      "evidence": "PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-[(PYRIDIN-3-YLMETHYL)-AMIDE] - Experimental MMP-13 inhibitor. No clinical trials, no atrial fibrillation indication. Related pyrimidine compounds cause cardiac toxicity but DB04761 itself has no AF connection. Source: DrugBank, PMC",
      "timestamp": "2026-01-20T00:00:00.000000"
    },
    "drkg:Compound::DB11775": {
      "classification": "NOVEL",
      "evidence": "PAK4 kinase inhibitor from patent US8530652. Investigated for cancer, not tuberculosis. Source: Google Patents, MedChemExpress, PNAS",
      "timestamp": "2026-01-19T22:59:19.284689"
    },
    "drkg:Compound::DB02620": {
      "classification": "NOVEL",
      "evidence": "Experimental compound with no clinical trials or TB indication. Source: DrugBank",
      "timestamp": "2026-01-19T22:59:19.284690"
    },
    "drkg:Compound::DB08562": {
      "classification": "NOVEL",
      "evidence": "Experimental styryl compound. Phenylbutyrate studied for TB but not this specific compound. Source: DrugBank, PLOS Pathogens",
      "timestamp": "2026-01-19T22:59:19.284691"
    },
    "drkg:Compound::DB12009": {
      "classification": "NOVEL",
      "evidence": "Experimental pyrazolopyridazine compound. No evidence as pharmaceutical drug or obesity treatment. Source: DrugBank",
      "timestamp": "2026-01-20T05:23:15.037147"
    },
    "drkg:Compound::DB07251": {
      "classification": "NOVEL",
      "evidence": "N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE - Already classified as NOVEL for tuberculosis. Experimental triazine compound, no AF indication. Source: DrugBank",
      "timestamp": "2026-01-20T00:00:00.000004"
    },
    "drkg:Compound::DB12572": {
      "classification": "NOVEL",
      "evidence": "CRF receptor antagonist for stress/anxiety disorders. No TB connection. Source: DrugBank",
      "timestamp": "2026-01-19T22:59:19.284693"
    },
    "drkg:Compound::DB02830": {
      "classification": "EXPERIMENTAL",
      "evidence": "FR236913 - Experimental BACE1 inhibitor. BACE1 is rate-limiting enzyme in amyloid-beta production, major AD therapeutic target. Compound in experimental development. Source: DrugBank, PMC9785888",
      "timestamp": "2026-01-19T23:54:01.843069"
    },
    "drkg:Compound::DB00718_TB": {
      "classification": "NOVEL",
      "evidence": "Adefovir Dipivoxil - FDA approved for Hepatitis B only, NOT for tuberculosis. Source: DrugBank, FDA",
      "timestamp": "2026-01-19T23:01:19.528572"
    },
    "drkg:Compound::DB15143": {
      "classification": "NOVEL",
      "evidence": "Zimlovisertib - IRAK4 inhibitor for rheumatoid arthritis, lupus. No TB indication. Source: MedChemExpress, Wikipedia",
      "timestamp": "2026-01-19T23:01:19.528573"
    },
    "drkg:Compound::DB02883_TB": {
      "classification": "NOVEL",
      "evidence": "Zalcitabine (ddC) - FDA approved antiretroviral for HIV only, NOT for tuberculosis. Source: Wikipedia, DrugBank",
      "timestamp": "2026-01-19T23:01:19.528574"
    },
    "drkg:Compound::DB11337": {
      "classification": "NOVEL",
      "evidence": "trans-Zeatin - Plant cytokinin hormone. No TB treatment indication. Source: DrugBank DB11337",
      "timestamp": "2026-01-19T23:01:19.528574"
    },
    "drkg:Compound::DB08562_BC": {
      "classification": "NOVEL",
      "evidence": "4-(4-STYRYL-PHENYLCARBAMOYL)-BUTYRIC ACID - Experimental styryl compound. Already classified as NOVEL for tuberculosis. No breast cancer indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    "drkg:Compound::DB14896": {
      "classification": "EXPERIMENTAL",
      "evidence": "Selitrectinib - TRK inhibitor for NTRK fusion-positive cancers. Phase I trial NCT03215511 includes solid tumors with NTRK fusions (can include breast cancer). Not specifically FDA approved for breast cancer. Source: MD Anderson, ClinicalTrials.gov",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    "drkg:Compound::DB08879": {
      "classification": "NOVEL",
      "evidence": "Belimumab - FDA approved monoclonal antibody for systemic lupus erythematosus, NOT breast cancer. Cancer risk monitoring in SLE patients only. Source: MSK, FDA label",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    "drkg:Compound::DB00618": {
      "classification": "NOVEL",
      "evidence": "Demeclocycline - Tetracycline antibiotic for bacterial infections. Used only for bone labeling in BC research studies, NOT as cancer treatment. Source: NCBI, ClinicalTrials NCT00873808",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    "drkg:Compound::DB07354": {
      "classification": "NOVEL",
      "evidence": "2,3-DIMETHOXY-12H-[1,3]DIOXOLO[5,6]INDENO[1,2-C]ISOQUINOLIN-6-IUM - Experimental isoquinoline compound. No breast cancer treatment evidence. Source: DrugBank",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    "drkg:Compound::DB12984": {
      "classification": "NOVEL",
      "evidence": "Larotaxel - Taxane chemotherapy agent investigated for various cancers. No obesity indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:24:27.215147"
    },
    "drkg:Compound::DB06094": {
      "classification": "EXPERIMENTAL",
      "evidence": "Apatorsen (OGX-427) - Antisense oligonucleotide targeting Hsp27. Phase I/II trials in breast cancer showed additive effect with chemotherapy. Source: AACR Abstract 3759, PubMed 27022067",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    "drkg:Compound::DB08393": {
      "classification": "NOVEL",
      "evidence": "2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL - Experimental furo[2,3-d]pyrimidine compound. No breast cancer indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    "drkg:Compound::DB08443": {
      "classification": "NOVEL",
      "evidence": "2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol - Experimental pyrrole compound. No clinical or breast cancer evidence. Source: DrugBank",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    "drkg:Compound::DB12089": {
      "classification": "NOVEL",
      "evidence": "Lorvotuzumab mertansine (IMGN901) - CD56-targeting ADC developed for small cell lung cancer and multiple myeloma. Development discontinued 2013/2014. No breast cancer trials. Source: Wikipedia, ADC Review",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    "drkg:Compound::DB10600": {
      "classification": "NOVEL",
      "evidence": "Influenza A virus vaccine - Inactivated flu vaccine antigen, not a cancer treatment. No breast cancer indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    "drkg:Compound::DB14755": {
      "classification": "NOVEL",
      "evidence": "beta-Isosparteine - Quinolizidine alkaloid. No clinical trials or breast cancer treatment indication found. Source: DrugBank",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    "drkg:Compound::DB11478": {
      "classification": "NOVEL",
      "evidence": "Zeranol - Anabolic growth promoter banned in EU. Research shows it PROMOTES breast cancer cell growth through estrogenic activity, not treats it. Source: BCPP, PubMed 21673905",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    "drkg:Compound::DB07883": {
      "classification": "NOVEL",
      "evidence": "(2-AMINO-3-PHENYL-BICYCLO[2.2.1]HEPT-2-YL)-PHENYL-METHANONE - Experimental bicyclic compound. No breast cancer indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    "drkg:Compound::DB12288": {
      "classification": "EXPERIMENTAL",
      "evidence": "Piromelatine - MT1/MT2 melatonin receptor agonist. Preclinical studies showed inhibition of weight gain, improved insulin sensitivity, reduced triglycerides in obese rats. Trials for insomnia only, no human obesity trials. Source: PubMed 24486392, JPET 364:55",
      "timestamp": "2026-01-20T05:23:15.037147"
    },
    "drkg:Compound::DB08056": {
      "classification": "NOVEL",
      "evidence": "N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine - Experimental imidazopyrazine compound. No breast cancer evidence. Source: DrugBank",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    "drkg:Compound::DB01398": {
      "classification": "NOVEL",
      "evidence": "Salicylate-sodium - Aspirin metabolite. Research shows chemopreventive effects (risk reduction), NOT treatment of established breast cancer. Source: Nature, PubMed 25380191",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    "drkg:Compound::DB00515": {
      "classification": "EXPERIMENTAL",
      "evidence": "Cisplatin - FDA approved for ovarian, testicular, bladder cancer. Used OFF-LABEL for triple-negative breast cancer with strong clinical rationale. Source: NCBI Bookshelf, LBBC",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    "drkg:Compound::DB12410": {
      "classification": "NOVEL",
      "evidence": "Sabarubicin (MEN 10755) - Anthracycline anticancer agent. Trials for prostate cancer, testicular cancer, solid tumors. No obesity indication. Source: DrugBank, Springer",
      "timestamp": "2026-01-20T05:23:15.037147"
    },
    "drkg:Compound::DB11679": {
      "classification": "EXPERIMENTAL",
      "evidence": "Fruquintinib - VEGFR1/2/3 inhibitor. FDA approved for colorectal cancer. Phase Ib/II trial NCT04577963 ongoing for breast cancer. Source: Springer, PMC4622458",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    "drkg:Compound::DB02647": {
      "classification": "NOVEL",
      "evidence": "N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide - Research compound, no drug development or therapeutic use found. Source: DrugBank",
      "timestamp": "2026-01-20T13:37:05.112593"
    },
    "drkg:Compound::DB07723": {
      "classification": "NOVEL",
      "evidence": "3-(5-methoxy-1H-indol-3-yl)propanoic acid - Experimental PPAR-gamma inhibitor. Structurally related to melatonin (shares 5-methoxy-indole core). While melatonin derivatives are studied for PD, this specific compound has 0 clinical trials and no PD indication. Source: DrugBank, ACS JMED",
      "timestamp": "2026-01-19T23:50:43.921334"
    },
    "drkg:Compound::DB08150": {
      "classification": "NOVEL",
      "evidence": "Experimental PKA inhibitor (cAMP-dependent protein kinase), not JAK inhibitor. No clinical data, no lung cancer indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:08:07.907709"
    },
    "drkg:Compound::DB02680": {
      "classification": "NOVEL",
      "evidence": "Industrial chemical and hazardous substance. Not approved, no clinical trials. Used as intermediate in pharmaceutical synthesis but not a drug itself. No lung cancer treatment role. Source: DrugBank, ATSDR",
      "timestamp": "2026-01-19T23:08:07.907709"
    },
    "drkg:Compound::DB11682": {
      "classification": "NOVEL",
      "evidence": "Daprodustat - HIF-PHI for anemia in chronic kidney disease. FDA approved Feb 2023. Seizures listed as adverse effect, NOT therapeutic indication. Source: WebMD, DrugBank",
      "timestamp": "2026-01-19T23:50:00.000002"
    },
    "drkg:Compound::DB11747": {
      "classification": "EXPERIMENTAL",
      "evidence": "AZD1152 - Aurora B kinase inhibitor. Phase II trials in small-cell lung cancer, Phase I in advanced solid tumors (23% stable disease, no objective responses, MTD 150-220mg). Showed tumor regression in SCLC xenografts at 100mg/kg. Source: AACR, PubMed 27496133",
      "timestamp": "2026-01-19T23:08:07.907709"
    },
    "drkg:Compound::DB06140": {
      "classification": "EXPERIMENTAL",
      "evidence": "SUVN-502 (Masupirdine) - 5-HT6 receptor antagonist. Phase II trial (NCT02580305) with donepezil+memantine for moderate AD. Missed primary endpoint (ADAS-cog) but showed benefits in behavioral symptoms. Source: PMC9157584, AlzForum",
      "timestamp": "2026-01-19T23:54:01.843066"
    },
    "drkg:Compound::DB14146": {
      "classification": "NOVEL",
      "evidence": "NKTR-181 - Mu-opioid agonist developed for chronic pain with low abuse potential. Development withdrawn after regulatory setback. Not a cancer treatment. Source: DrugBank, Nektar",
      "timestamp": "2026-01-19T23:08:07.907709"
    },
    "drkg:Compound::DB07583": {
      "classification": "NOVEL",
      "evidence": "(4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE - Research compound, no drug development or clinical indication. Source: DrugBank",
      "timestamp": "2026-01-20T13:37:05.112601"
    },
    "drkg:Compound::DB07626": {
      "classification": "NOVEL",
      "evidence": "4-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide - Research compound, no drug development or clinical indication found. Source: DrugBank",
      "timestamp": "2026-01-20T13:37:05.112586"
    },
    "drkg:Compound::DB07059": {
      "classification": "NOVEL",
      "evidence": "Experimental pyrimidine-benzoxazin compound with no clinical trials or colorectal cancer indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:15:00.000002"
    },
    "drkg:Compound::DB07276": {
      "classification": "NOVEL",
      "evidence": "Experimental pyridine carboxamide compound with no clinical trials or colorectal cancer indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:15:00.000003"
    },
    "drkg:Compound::DB03733": {
      "classification": "NOVEL",
      "evidence": "1,2-dichloroethane - Industrial solvent and known carcinogen, not a therapeutic agent. EPA classified as Group B2 probable human carcinogen. Source: EPA IRIS, PubMed",
      "timestamp": "2026-01-19T23:15:00.000004"
    },
    "drkg:Compound::DB05188": {
      "classification": "NOVEL",
      "evidence": "KD3010 - PPAR-delta agonist investigated for metabolic disorders and obesity. No colorectal cancer indication. Source: DrugBank, MedChemExpress",
      "timestamp": "2026-01-19T23:15:00.000005"
    },
    "drkg:Compound::DB05142": {
      "classification": "NOVEL",
      "evidence": "ND7001 - No evidence found in asthma literature or clinical trials databases. Source: ClinicalTrials.gov, PubMed",
      "timestamp": "2026-01-20T05:28:19.441422"
    },
    "drkg:Compound::DB08068": {
      "classification": "NOVEL",
      "evidence": "Experimental chloro-pyridine compound with no clinical trials or colorectal cancer indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:15:00.000007"
    },
    "drkg:Compound::DB08276": {
      "classification": "NOVEL",
      "evidence": "Beryllium phosphonate complex - Experimental compound, no COPD indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:59.267206"
    },
    "drkg:Compound::DB07719": {
      "classification": "NOVEL",
      "evidence": "Experimental tetrahydroisoquinoline sulfamic acid compound with no clinical trials or colorectal cancer indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:15:00.000009"
    },
    "drkg:Compound::DB10772": {
      "classification": "NOVEL",
      "evidence": "Foreskin keratinocyte (neonatal) - Cell therapy for skin grafts/wound healing, not a drug. Used for burns and chronic wounds. No osteoporosis indication. Source: DrugBank, PubMed 23495214",
      "timestamp": "2026-01-20T13:37:05.112598"
    },
    "drkg:Compound::DB14935": {
      "classification": "NOVEL",
      "evidence": "Serabelisib (TAK-117) - PI3K-alpha inhibitor for solid tumors with PIK3CA mutations. No osteoporosis or bone indication. Source: NCI, DrugBank",
      "timestamp": "2026-01-20T13:37:05.112589"
    },
    "drkg:Compound::DB12410_CRC": {
      "classification": "NOVEL",
      "evidence": "Sabarubicin - Anthracycline tested in Phase II for prostate cancer and lung cancer. Only preclinical research in CRC (HCT-116 cell line), no clinical trials for colorectal cancer. Source: PubMed 18038274, DrugBank",
      "timestamp": "2026-01-19T23:15:00.000012"
    },
    "drkg:Compound::DB11747_CRC": {
      "classification": "NOVEL",
      "evidence": "Barasertib (AZD1152) - Aurora B kinase inhibitor. Phase I trials in solid tumors showed 23% stable disease. Preclinical CRC evidence only, no dedicated CRC trials. Development stalled due to myelotoxicity. Source: PubMed 22661287, PMC",
      "timestamp": "2026-01-19T23:15:00.000013"
    },
    "drkg:Compound::DB02472": {
      "classification": "NOVEL",
      "evidence": "7,8-dihydroinosine - Experimental purine nucleoside analog. No clinical indication, no colorectal cancer evidence. Source: DrugBank",
      "timestamp": "2026-01-19T23:30:00.000000"
    },
    "drkg:Compound::DB06977": {
      "classification": "NOVEL",
      "evidence": "(2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}... - Experimental research compound. No RA indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:55:56.850432"
    },
    "drkg:Compound::DB07146": {
      "classification": "NOVEL",
      "evidence": "2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE - Lck kinase inhibitor discovered 2007. No colorectal cancer indication. Source: DrugBank, Bioorg Med Chem Lett",
      "timestamp": "2026-01-19T23:30:00.000002"
    },
    "drkg:Compound::DB08200": {
      "classification": "NOVEL",
      "evidence": "(1R)-menthyl hexyl phosphonate - Experimental phosphonate compound, no COPD treatment indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:16.349828"
    },
    "drkg:Compound::DB07088": {
      "classification": "NOVEL",
      "evidence": "(S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide - Experimental compound. Related pyrrolidine carboxamides studied for HCC but not CRC. Source: DrugBank",
      "timestamp": "2026-01-19T23:30:00.000004"
    },
    "drkg:Compound::DB03359": {
      "classification": "NOVEL",
      "evidence": "M-(N,N,N-Trimethylammonio)-2,2,2-Trifluoro-1,1-Dihydroxyethylbenzene - Experimental small molecule, no indicated conditions, no CRC connection. Source: DrugBank",
      "timestamp": "2026-01-19T23:30:00.000005"
    },
    "drkg:Compound::DB02112": {
      "classification": "NOVEL",
      "evidence": "ZK-806450 - No information found in clinical trial databases or literature. Likely experimental compound with no CRC trials. Source: ClinicalTrials.gov search",
      "timestamp": "2026-01-19T23:30:00.000006"
    },
    "drkg:Compound::DB08148": {
      "classification": "NOVEL",
      "evidence": "1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine - Pyrimidinyl derivative from anticancer patent. No clinical trials, no CRC evidence. Source: DrugBank, WO2003018021A1",
      "timestamp": "2026-01-19T23:30:00.000007"
    },
    "drkg:Compound::DB03759": {
      "classification": "NOVEL",
      "evidence": "FG-9041 (DNQX) - Non-NMDA glutamate (AMPA/kainate) receptor antagonist used in molecular biology research. Not specifically developed for AD. Source: DrugBank, MedChemExpress",
      "timestamp": "2026-01-19T23:54:01.843068"
    },
    "drkg:Compound::DB03376": {
      "classification": "NOVEL",
      "evidence": "5'-O-(N-(Alanyl)sulfamoyl)adenosine - Analog of alanyl-AMP for studying tRNA synthetase. Research tool, not therapeutic. No CRC connection. Source: DrugBank, PubMed 1932086",
      "timestamp": "2026-01-19T23:30:00.000009"
    },
    "drkg:Compound::DB07467": {
      "classification": "NOVEL",
      "evidence": "(S)-Indapamide - Thiazide-like diuretic for hypertension, not COPD treatment. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:59.267207"
    },
    "drkg:Compound::DB00502": {
      "classification": "NOVEL",
      "evidence": "Haloperidol - Antipsychotic for schizophrenia. Causes hypotension (<10% patients) as side effect, not a hypertension treatment. Contraindicated in severe cardiovascular disorders. Source: DrugBank, FDA warning",
      "timestamp": "2026-01-19T23:17:55.247644"
    },
    "drkg:Compound::DB00901": {
      "classification": "NOVEL",
      "evidence": "Bitolterol - Beta-2 agonist for asthma/COPD. Withdrawn 2001 by Elan Pharmaceuticals. Not for hypertension; elevated BP was a side effect to monitor. Source: DrugBank, MedNet",
      "timestamp": "2026-01-19T23:17:55.247645"
    },
    "drkg:Compound::DB00320": {
      "classification": "NOVEL",
      "evidence": "Dihydroergotamine - Ergot alkaloid for migraine via serotonin receptor agonism. CONTRAINDICATED in uncontrolled hypertension; may increase BP. Source: DrugBank, FDA label",
      "timestamp": "2026-01-19T23:17:55.247646"
    },
    "drkg:Compound::DB00532": {
      "classification": "NOVEL",
      "evidence": "Mephenytoin - Hydantoin anticonvulsant for epilepsy. No longer available in US/UK due to blood dyscrasia risk. No hypertension indication. Source: DrugBank, ScienceDirect",
      "timestamp": "2026-01-19T23:17:55.247646"
    },
    "drkg:Compound::DB05070": {
      "classification": "NOVEL",
      "evidence": "ADX10059 - mGluR5 antagonist developed for GERD/migraine. Already classified for epilepsy/Parkinson's. No obesity indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:24:27.215147"
    },
    "drkg:Compound::DB13908": {
      "classification": "NOVEL",
      "evidence": "Amylmetacresol - Antiseptic used in throat lozenges (Strepsils). No Parkinson disease connection. Source: DrugBank, Wikipedia",
      "timestamp": "2026-01-19T23:49:30.061145"
    },
    "drkg:Compound::DB12149": {
      "classification": "NOVEL",
      "evidence": "S-3304 - Already classified as NOVEL for hypertension. Matrix metalloproteinase inhibitor for cancer. No AF indication. Source: PubMed 17404091",
      "timestamp": "2026-01-20T00:00:00.000006"
    },
    "drkg:Compound::DB12608": {
      "classification": "NOVEL",
      "evidence": "Emixustat - Investigated for geographic atrophy and age-related macular degeneration. Small molecule for eye conditions, not cardiovascular. Source: DrugBank DB12608",
      "timestamp": "2026-01-19T23:17:55.247648"
    },
    "drkg:Compound::DB12067": {
      "classification": "NOVEL",
      "evidence": "BMS-394136 - Kv1.5 potassium channel antagonist for atrial fibrillation and cardiac arrhythmias. Phase I trials in patients with pacemakers/defibrillators. Not for hypertension. Source: DrugBank, ClinicalTrials NCT00162448, MedChemExpress",
      "timestamp": "2026-01-19T23:17:55.247649"
    },
    "drkg:Compound::DB06619_HF": {
      "classification": "NOVEL",
      "evidence": "Amdoxovir - Investigational NRTI for HIV only, NOT for heart failure. No cardiovascular indication. Source: NIH AIDSinfo, DrugBank",
      "timestamp": "2026-01-19T23:20:50.724468"
    },
    "drkg:Compound::DB02647_HF": {
      "classification": "NOVEL",
      "evidence": "N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide - Already classified as NOVEL for lung cancer. Experimental benzamide, no heart failure indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:20:50.724471"
    },
    "drkg:Compound::DB15019_HF": {
      "classification": "NOVEL",
      "evidence": "DB15019 - Already classified as NOVEL for HIV. Unable to identify specific drug, no heart failure evidence. Source: DrugBank",
      "timestamp": "2026-01-19T23:20:50.724472"
    },
    "drkg:Compound::DB06231": {
      "classification": "EXPERIMENTAL",
      "evidence": "Caldaret - Intracellular Ca2+ handling modulator. Phase II CASTEMI trial for ST-elevation myocardial infarction undergoing primary PCI. Investigated for heart disease and myocardial infarction. Trial showed no benefit vs placebo for infarct size; CHF by 30 days was 15.7% placebo vs 21.6% low dose. Source: ACC, PubMed 17299242",
      "timestamp": "2026-01-19T23:20:50.724473"
    },
    "drkg:Compound::DB14143_HF": {
      "classification": "NOVEL",
      "evidence": "Dimethyldioctadecylammonium - Already classified as NOVEL for HIV. Vaccine adjuvant, not a heart failure treatment. Source: DrugBank",
      "timestamp": "2026-01-19T23:20:50.724473"
    },
    "drkg:Compound::DB04614": {
      "classification": "NOVEL",
      "evidence": "(R)-tacrine(10)-hupyridone - Experimental hybrid compound. No indicated conditions, no heart failure trials. Tacrine causes pressor/bradycardic effects but no HF treatment indication. Source: DrugBank, ScienceDirect",
      "timestamp": "2026-01-19T23:20:50.724474"
    },
    "drkg:Compound::DB03365": {
      "classification": "NOVEL",
      "evidence": "4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline - CDK2 inhibitor investigated for cancer (EGFR targeting). No heart failure indication. Source: DrugBank, PubMed",
      "timestamp": "2026-01-19T23:20:50.724474"
    },
    "drkg:Compound::DB02504": {
      "classification": "NOVEL",
      "evidence": "[3-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Propyl-]-Phosphonic Acid - Experimental compound. No heart failure indication found. Source: PDB, HMDB",
      "timestamp": "2026-01-19T23:20:50.724475"
    },
    "drkg:Compound::DB07279": {
      "classification": "NOVEL",
      "evidence": "Experimental benzamide compound. No evidence as pharmaceutical drug or obesity treatment. Source: DrugBank",
      "timestamp": "2026-01-20T05:23:15.037147"
    },
    "drkg:Compound::DB08200_HF": {
      "classification": "NOVEL",
      "evidence": "(1R)-menthyl hexyl phosphonate group - Already classified as NOVEL for colorectal cancer. Experimental cholinesterase inhibitor, no heart failure indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:20:50.724476"
    },
    "drkg:Compound::DB10713": {
      "classification": "NOVEL",
      "evidence": "Poa compressa pollen - Allergen extract for allergy immunotherapy. Not a cardiovascular drug. Source: DrugBank",
      "timestamp": "2026-01-19T23:20:50.724477"
    },
    "drkg:Compound::DB03935": {
      "classification": "NOVEL",
      "evidence": "1,4-Dideoxy-O2-Sulfo-Glucuronic Acid - Experimental carbohydrate research compound. No AD indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:54:01.843064"
    },
    "drkg:Compound::DB04173": {
      "classification": "NOVEL",
      "evidence": "beta-L-fructofuranose - Sugar metabolite, no asthma treatment indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:29:49.293195"
    },
    "drkg:Compound::DB15112": {
      "classification": "EXPERIMENTAL",
      "evidence": "Somatropin pegol (NNC126-0083) - PEGylated growth hormone investigated in trial NCT00715689 for GH deficiency. Some evidence that GH therapy improves hemodynamics in HF patients, but this specific drug is in early trials for GHD. Source: NCATS, PubMed 15981951",
      "timestamp": "2026-01-19T23:20:50.724586"
    },
    "drkg:Compound::DB06869": {
      "classification": "NOVEL",
      "evidence": "1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE - Experimental compound with no approved status or indicated conditions. No heart failure evidence. Source: DrugBank",
      "timestamp": "2026-01-19T23:20:50.724587"
    },
    "drkg:Compound::DB11938_HF": {
      "classification": "NOVEL",
      "evidence": "Difelikefalin - Already classified as NOVEL for HIV. Kappa opioid agonist for uremic pruritus, not a heart failure treatment. Source: DrugBank",
      "timestamp": "2026-01-19T23:20:50.724587"
    },
    "drkg:Compound::DB08393_HF": {
      "classification": "NOVEL",
      "evidence": "2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL - Already classified as NOVEL for breast cancer. Experimental compound, no heart failure indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:20:50.724588"
    },
    "drkg:Compound::DB08276_HF": {
      "classification": "NOVEL",
      "evidence": "trifluoro-[hydroxy-[hydroxy-[2-(N-methyl-2-nitro-anilino)ethoxy]phosphoryl]oxy-phosphoryl]oxy-beryllium(1-) - Already classified as NOVEL for colorectal cancer. Experimental beryllium compound, no heart failure indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:20:50.724588"
    },
    "drkg:Compound::DB11607_HF": {
      "classification": "NOVEL",
      "evidence": "Efmoroctocog alfa (Elocta) - Already classified as NOVEL for HIV. Recombinant Factor VIII for Hemophilia A, not a heart failure treatment. Source: DrugBank",
      "timestamp": "2026-01-19T23:20:50.724589"
    },
    "drkg:Compound::DB07626_HF": {
      "classification": "NOVEL",
      "evidence": "4-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide - Already classified as NOVEL for colorectal cancer. Experimental benzamide, no heart failure indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:20:50.724590"
    },
    "drkg:Compound::DB11852_HF": {
      "classification": "NOVEL",
      "evidence": "Tegobuvir - Already classified as NOVEL for HIV. HCV NS5B polymerase inhibitor, not for heart failure. Source: DrugBank",
      "timestamp": "2026-01-19T23:20:50.724590"
    },
    "drkg:Compound::DB13908_HF": {
      "classification": "NOVEL",
      "evidence": "Amylmetacresol - Already classified as NOVEL for hypertension. Antiseptic for sore throat, no cardiovascular indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:20:50.724591"
    },
    "drkg:Compound::DB07143": {
      "classification": "NOVEL",
      "evidence": "D-phenylalanyl-N-benzyl-L-prolinamide - Experimental small molecule with no indication available. No epilepsy or anticonvulsant evidence. Source: DrugBank",
      "timestamp": "2026-01-20T00:00:00.000015"
    },
    "drkg:Compound::DB14875": {
      "classification": "NOVEL",
      "evidence": "AZD 4017 - Potent 11\u03b2-HSD1 inhibitor (IC50: 7nM) for Type 2 diabetes and metabolic conditions. Improves cardiovascular risk factors (cholesterol, BP) but not developed or studied for AF treatment. Source: MedChemExpress, PMC8942338",
      "timestamp": "2026-01-20T01:00:00.000001"
    },
    "drkg:Compound::DB02425": {
      "classification": "NOVEL",
      "evidence": "Caprylic acid, cetyl ester - Fatty acid ester compound. No atrial fibrillation treatment indication. Source: DrugBank",
      "timestamp": "2026-01-20T01:00:00.000002"
    },
    "drkg:Compound::DB13917": {
      "classification": "NOVEL",
      "evidence": "Deoxyepinephrine (epinine) - Catecholamine compound. Epinephrine can CAUSE AF as side effect, not a treatment. No AF therapeutic indication for deoxyepinephrine. Source: PMC9812684",
      "timestamp": "2026-01-20T01:00:00.000003"
    },
    "drkg:Compound::DB12080": {
      "classification": "NOVEL",
      "evidence": "Ritobegron (KUC-7483) - \u03b23-adrenergic receptor agonist for overactive bladder. Related drug mirabegron INCREASES AF risk (HR 1.30). Not an AF treatment. Source: JAMA Internal Medicine, PMC6632155",
      "timestamp": "2026-01-20T01:00:00.000004"
    },
    "drkg:Compound::DB01634": {
      "classification": "NOVEL",
      "evidence": "2-Oxy-4-Hydroxy-5-(2-Hydrazinopyridine)Phenylalanine - Complex compound, no asthma indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:28:19.441425"
    },
    "drkg:Compound::DB05098": {
      "classification": "EXPERIMENTAL",
      "evidence": "Leptin - Adipokine hormone. Leptin signaling essential for angiotensin II-evoked atrial fibrosis/fibrillation. Modulates atrial electrophysiology and isoproterenol-induced arrhythmogenesis. Hyperleptinemia increases AF risk (OR 1.02). Investigated for AF pathophysiology role. Source: Circulation Arrhythmia EP 2013, J Biomed Sci 2013",
      "timestamp": "2026-01-20T01:00:00.000006"
    },
    "drkg:Compound::DB13316": {
      "classification": "EXPERIMENTAL",
      "evidence": "Ibopamine - Dopamine receptor agonist (DA-1/DA-2). PRIME II trial tested in advanced heart failure patients. Trial stopped early due to increased mortality (RR 1.26, p=0.017). Antiarrhythmic drug use at baseline was significant predictor of increased mortality in ibopamine-treated patients. Source: Lancet 1997, PubMed 9100622",
      "timestamp": "2026-01-20T01:00:00.000007"
    },
    "drkg:Compound::DB06280": {
      "classification": "EXPERIMENTAL",
      "evidence": "Senicapoc (ICA-17043) - KCa3.1 Gardos channel blocker. Research shows KCa3.1 blockade suppresses AF by attenuating cardiac fibroblast activity and atrial fibrosis. Well-tolerated in sickle cell trials, potential for rapid translation to AF treatment. Source: ResearchGate, DrugBank",
      "timestamp": "2026-01-20T01:00:00.000008"
    },
    "drkg:Compound::DB00190": {
      "classification": "NOVEL",
      "evidence": "Carbidopa - Used with levodopa for Parkinson's disease. Can CAUSE adverse cardiac effects including AF, atrial flutter, arrhythmia as side effects. Not an AF treatment. Source: Drugs.com, PubMed 24819390",
      "timestamp": "2026-01-20T01:00:00.000009"
    },
    "drkg:Compound::DB06868": {
      "classification": "NOVEL",
      "evidence": "N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide - Experimental peptide research compound. No RA indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:55:56.850434"
    },
    "drkg:Compound::DB09422": {
      "classification": "NOVEL",
      "evidence": "Soybean oil - Nutritional supplement and pharmaceutical excipient. Omega-3 studies show mixed/increased AF risk with supplementation. Not an AF treatment. Source: PMC10175873",
      "timestamp": "2026-01-19T23:36:28.382912"
    },
    "drkg:Compound::DB05345": {
      "classification": "NOVEL",
      "evidence": "SO-101 - Low-dose doxepin for insomnia. Histamine antagonist. Experimental, not approved. No obesity indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:24:27.215147"
    },
    "drkg:Compound::DB08010": {
      "classification": "NOVEL",
      "evidence": "Experimental benzodioxin-indole compound. 0 clinical trials, no indicated conditions, no AF connection. Source: DrugBank",
      "timestamp": "2026-01-19T23:36:28.382912"
    },
    "drkg:Compound::DB08836": {
      "classification": "EXPERIMENTAL",
      "evidence": "Temocapril - ACE inhibitor approved in Japan/South Korea for hypertension and heart failure. ACE inhibitors as class reduce AF risk by 28% in meta-analysis, greatest benefit in HF (44% RRR). Not specifically studied for AF but class effect supports benefit. Source: DrugBank, ScienceDirect",
      "timestamp": "2026-01-19T23:36:28.382912"
    },
    "drkg:Compound::DB11732": {
      "classification": "NOVEL",
      "evidence": "Lasmiditan - Selective 5-HT1F receptor agonist for acute migraine. FDA approved 2019. Cardiac arrhythmia reports (palpitations, tachycardia) in trials but no AF indication. No vasoconstriction, cardiovascularly safe. Source: PMC6734241, PMC6787764",
      "timestamp": "2026-01-19T23:36:28.382912"
    },
    "drkg:Compound::DB03868": {
      "classification": "NOVEL",
      "evidence": "3-dehydroquinic acid - Metabolic intermediate in the shikimate pathway (plants/microbes). Not a therapeutic drug. No AF indication. Source: DrugBank",
      "timestamp": "2026-01-20T00:00:00.000001"
    },
    "drkg:Compound::DB03110": {
      "classification": "NOVEL",
      "evidence": "2-Chlorophenol - Industrial chemical, disinfectant, chemical intermediate. Not a therapeutic drug. Toxic. No diabetes application. Source: DrugBank, PubChem",
      "timestamp": "2026-01-20T05:21:18.961630"
    },
    "drkg:Compound::DB14010": {
      "classification": "NOVEL",
      "evidence": "5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) - Psychedelic tryptamine. Research shows it affects atrial contractility and heart rate via 5-HT4 receptors, but NOT an AF treatment. Source: Nature Scientific Reports 2025",
      "timestamp": "2026-01-20T00:00:00.000005"
    },
    "drkg:Compound::DB14502": {
      "classification": "NOVEL",
      "evidence": "Sodium phosphate, dibasic - Electrolyte supplement and pH buffer. Not an antiarrhythmic or AF treatment. Source: DrugBank",
      "timestamp": "2026-01-20T00:00:00.000007"
    },
    "drkg:Compound::DB09351": {
      "classification": "EXPERIMENTAL",
      "evidence": "Levobetaxolol - Cardioselective \u03b21-blocker. FDA approved ONLY as ophthalmic solution for glaucoma (0.5% eye drops, trade name Betaxon, discontinued). Beta-blockers as class treat AF, but levobetaxolol used exclusively for eye conditions, not systemic cardiac use. Source: DrugBank, PMC2704505",
      "timestamp": "2026-01-20T00:00:00.000008"
    },
    "drkg:Compound::DB09477": {
      "classification": "CONFIRMED",
      "evidence": "Enalaprilat - IV form of enalapril, ACE inhibitor. Reduces AF risk by 28% in meta-analysis (56,308 patients). Prevents atrial remodeling and fibrosis. Greatest benefit in heart failure patients (44% RR reduction). Used to prevent and treat AF. Source: Circulation 2003, Cardiovascular Research 2002",
      "timestamp": "2026-01-20T00:00:00.000009"
    },
    "drkg:Compound::DB01944": {
      "classification": "NOVEL",
      "evidence": "(S)-blebbistatin - Myosin II inhibitor. Research tool for cell biology. No epilepsy or anticonvulsant evidence found. Source: DrugBank",
      "timestamp": "2026-01-19T23:50:00.000004"
    },
    "drkg:Compound::DB12410_epilepsy": {
      "classification": "NOVEL",
      "evidence": "Sabarubicin - Anthracycline tested in cancer trials (lung, breast). No epilepsy or neurological indication. Source: PubMed 18038274",
      "timestamp": "2026-01-19T23:50:00.000005"
    },
    "drkg:Compound::DB15207": {
      "classification": "NOVEL",
      "evidence": "Esaxerenone - Selective mineralocorticoid receptor blocker for hypertension in Japan. No epilepsy indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:50:00.000006"
    },
    "drkg:Compound::DB02647_epilepsy": {
      "classification": "NOVEL",
      "evidence": "N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide - Experimental benzamide compound. Related compounds studied as PAK4 inhibitors in cancer (preclinical), no epilepsy connection. Source: DrugBank, MDPI",
      "timestamp": "2026-01-19T23:50:00.000007"
    },
    "drkg:Compound::DB12567_epilepsy": {
      "classification": "NOVEL",
      "evidence": "Camicinal (GSK962040) - Motilin receptor agonist for gastroparesis. Development discontinued. No epilepsy connection. Source: DrugBank, Wikipedia",
      "timestamp": "2026-01-19T23:50:00.000009"
    },
    "drkg:Compound::DB08599": {
      "classification": "NOVEL",
      "evidence": "N-[(4-methoxyphenyl)sulfonyl]-D-alanine - Experimental compound with no indication available. No epilepsy or anticonvulsant evidence. Source: DrugBank, PubChem CID 705712",
      "timestamp": "2026-01-20T00:00:00.000010"
    },
    "drkg:Compound::DB12149_epilepsy": {
      "classification": "NOVEL",
      "evidence": "S 3304 - Matrix metalloproteinase (MMP) inhibitor for cancer (lung, solid tumors). Phase I trials only. No epilepsy indication. Source: PubMed 17404091, DrugBank",
      "timestamp": "2026-01-20T00:00:00.000012"
    },
    "drkg:Compound::DB04256": {
      "classification": "EXPERIMENTAL",
      "evidence": "(S)-alpha-methyl-4-carboxyphenylglycine (S-MCPG) - mGluR1a antagonist. Showed weak anticonvulsant activity in preclinical seizure models. Modulates seizure activity via mGluR1a/mGluR2. Source: PubMed 8189254, 8632317",
      "timestamp": "2026-01-20T00:00:00.000013"
    },
    "drkg:Compound::DB12253_epilepsy": {
      "classification": "NOVEL",
      "evidence": "Brilanestrant (GDC-0810) - Estrogen receptor antagonist/degrader for breast cancer. Phase II trials discontinued 2017. No epilepsy indication. Source: Wikipedia, DrugBank",
      "timestamp": "2026-01-20T00:00:00.000016"
    },
    "drkg:Compound::DB01671": {
      "classification": "NOVEL",
      "evidence": "p-Hydroxymercuribenzoic acid - Mercury-containing compound used as biochemical reagent. No epilepsy or clinical indication. Source: DrugBank",
      "timestamp": "2026-01-20T00:00:00.000017"
    },
    "drkg:Compound::DB07480": {
      "classification": "NOVEL",
      "evidence": "4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN - Experimental phosphate compound with no indication or epilepsy evidence. Source: DrugBank",
      "timestamp": "2026-01-20T00:00:00.000018"
    },
    "drkg:Compound::DB08430": {
      "classification": "NOVEL",
      "evidence": "PARA-NITROPHENYL 1-THIO-BETA-D-GLUCOPYRANOSIDE - Experimental sugar derivative with no clinical indication or epilepsy evidence. Source: DrugBank",
      "timestamp": "2026-01-20T00:00:00.000019"
    },
    "drkg:Compound::DB03526": {
      "classification": "NOVEL",
      "evidence": "AL5927 - Research compound. No specific information found linking to Parkinson disease treatment. Source: DrugBank",
      "timestamp": "2026-01-19T23:49:30.061140"
    },
    "drkg:Compound::DB11962": {
      "classification": "NOVEL",
      "evidence": "GSK 1059615 - PI3K/mTOR inhibitor for cancer. PI3K pathway is osteoanabolic; inhibition would impair bone formation, not treat osteoporosis. Phase I cancer trials only. Source: AdooQ, PMC1950686",
      "timestamp": "2026-01-20T13:37:05.112480"
    },
    "drkg:Compound::DB12847": {
      "classification": "NOVEL",
      "evidence": "Pyroxamide - HDAC inhibitor investigated for leukemia/lymphoma/cancer. No Parkinson disease connection found. Source: DrugBank",
      "timestamp": "2026-01-19T23:49:30.061142"
    },
    "drkg:Compound::DB15212": {
      "classification": "NOVEL",
      "evidence": "Pemafibrate - PPAR-alpha agonist for NAFLD (NCT03350165). No Parkinson disease indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:49:30.061143"
    },
    "drkg:Compound::DB11772": {
      "classification": "EXPERIMENTAL",
      "evidence": "Pilaralisib (XL-147) - Pan-PI3K inhibitor investigated for cancer. PI3K/AKT/mTOR pathway is RA therapeutic target; inhibition suppresses RA fibroblast-like synoviocytes. Class mechanism relevance. Source: DrugBank, MDPI 1424-8247/18/8/1152",
      "timestamp": "2026-01-19T23:55:56.850433"
    },
    "drkg:Compound::DB06440": {
      "classification": "NOVEL",
      "evidence": "Ravuconazole - Discontinued triazole antifungal (development stopped 2007). No PD indication. Note: General antifungal exposure associated with modest PD risk increase but not a PD treatment. Source: Wikipedia, Springer AdisInsight",
      "timestamp": "2026-01-19T23:49:30.061144"
    },
    "drkg:Compound::DB11865": {
      "classification": "NOVEL",
      "evidence": "Brivanib alaninate - VEGF/FGFR dual inhibitor for hepatocellular carcinoma. Development discontinued. No osteoporosis indication. Source: Wikipedia, PubMed 18829493",
      "timestamp": "2026-01-20T13:37:05.112580"
    },
    "drkg:Compound::DB12302": {
      "classification": "NOVEL",
      "evidence": "CP-724,714 - Selective HER2/ErbB2 tyrosine kinase inhibitor for cancer. Development discontinued due to hepatotoxicity. No Parkinson disease indication. Source: Cancer Research, PubMed 17942920",
      "timestamp": "2026-01-19T23:50:43.921332"
    },
    "drkg:Compound::DB01966": {
      "classification": "NOVEL",
      "evidence": "Di-Stearoyl-3-Sn-Phosphatidylethanolamine - Phospholipid, no COPD treatment indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:59.267205"
    },
    "drkg:Compound::DB05466": {
      "classification": "NOVEL",
      "evidence": "R673 - NK1 antagonist developed for depression and anxiety, not Alzheimer's. Phase II program was for psychiatric conditions. No AD clinical trials. Source: DrugBank, IUPHAR",
      "timestamp": "2026-01-19T23:54:01.843062"
    },
    "drkg:Compound::DB08374": {
      "classification": "NOVEL",
      "evidence": "Phenylalanylmethylchloride - Experimental research compound. No Alzheimer's disease indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:54:01.843063"
    },
    "drkg:Compound::DB03405": {
      "classification": "NOVEL",
      "evidence": "N2-[(Benzyloxy)carbonyl]... leucinamide - Experimental peptide research compound. No AD evidence. Source: DrugBank",
      "timestamp": "2026-01-19T23:54:01.843063"
    },
    "drkg:Compound::DB07734": {
      "classification": "NOVEL",
      "evidence": "N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide - Experimental research compound. No AD evidence. Source: DrugBank",
      "timestamp": "2026-01-19T23:54:01.843065"
    },
    "drkg:Compound::DB06371": {
      "classification": "NOVEL",
      "evidence": "Siplizumab (MEDI-507) - Humanized IgG1 anti-CD2 monoclonal antibody for T-cell mediated conditions (psoriasis, GVHD). No AD connection. Source: DrugBank, PMC7686512",
      "timestamp": "2026-01-19T23:54:01.843066"
    },
    "drkg:Compound::DB14877": {
      "classification": "EXPERIMENTAL",
      "evidence": "Lintuzumab (HuM195) - Anti-CD33 monoclonal antibody. CD33 is AD risk factor and genetic target. Research shows CD33 antibodies may reduce AD risk. Preclinical evidence only. Source: Nature Mol Psychiatry 2024, PMC4498153",
      "timestamp": "2026-01-19T23:54:01.843067"
    },
    "drkg:Compound::DB00281": {
      "classification": "NOVEL",
      "evidence": "Lidocaine - Local anesthetic. Attenuates anesthesia-induced cognitive impairment in preclinical models but not an AD treatment. Does not affect amyloid or tau. Source: PMC3268839",
      "timestamp": "2026-01-19T23:54:01.843068"
    },
    "drkg:Compound::DB05006": {
      "classification": "NOVEL",
      "evidence": "Adecatumumab - Anti-EpCAM monoclonal antibody for breast and prostate cancer. No AD connection. Source: DrugBank, PubMed 20426706",
      "timestamp": "2026-01-19T23:54:01.843069"
    },
    "drkg:Compound::DB00081": {
      "classification": "EXPERIMENTAL",
      "evidence": "Tositumomab - Murine IgG2a anti-CD20 monoclonal antibody. FDA approved for B-cell non-Hodgkin's lymphoma. CD20 antibody class (rituximab) is used for RA, but tositumomab itself not specifically tested for RA. Source: DrugBank, Springer",
      "timestamp": "2026-01-19T23:55:56.850432"
    },
    "drkg:Compound::DB08254": {
      "classification": "NOVEL",
      "evidence": "2-Naphthalenesulfonic acid - Industrial chemical compound. No RA indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:55:56.850435"
    },
    "drkg:Compound::DB01240": {
      "classification": "EXPERIMENTAL",
      "evidence": "Epoprostenol (Prostacyclin) - FDA approved for pulmonary hypertension. Prostacyclin analog iloprost studied in RA (7-day trial showed TNF-alpha reduction, clinical improvement). Class mechanism relevance. Source: PubMed 12070674, PMC3407649",
      "timestamp": "2026-01-19T23:55:56.850436"
    },
    "drkg:Compound::DB04853": {
      "classification": "EXPERIMENTAL",
      "evidence": "Binodenoson - Selective A2A adenosine receptor agonist for cardiac stress imaging. A2A receptor stimulation is anti-inflammatory in RA; research supports A2A agonists as RA treatment. Class mechanism relevance. Source: DrugBank, Science Transl Med 2013",
      "timestamp": "2026-01-19T23:55:56.850436"
    },
    "drkg:Compound::DB12102": {
      "classification": "NOVEL",
      "evidence": "Fulranumab - Anti-NGF monoclonal antibody for pain (OA, neuropathic). Development halted 2016 due to safety concerns. No MS connection. Source: DrugBank, PMC4141990",
      "timestamp": "2026-01-19T23:57:46.977758"
    },
    "drkg:Compound::DB12917": {
      "classification": "EXPERIMENTAL",
      "evidence": "Bimekizumab - Dual IL-17A/IL-17F inhibitor. FDA approved for psoriasis/PsA. IL-17A critical in EAE (MS mouse model); IL-17A suppression reduces EAE severity. Class mechanism relevance to MS. Source: PMC7473305, PMC10514131",
      "timestamp": "2026-01-19T23:57:46.977761"
    },
    "drkg:Compound::DB06474": {
      "classification": "NOVEL",
      "evidence": "Sibrotuzumab - Anti-FAP (fibroblast activation protein) antibody for cancer. No MS connection. Source: DrugBank",
      "timestamp": "2026-01-19T23:57:46.977762"
    },
    "drkg:Compound::DB06557": {
      "classification": "NOVEL",
      "evidence": "Lerdelimumab - Anti-TGF-beta2 humanized antibody for scarring prevention. No MS indication. Source: DrugBank",
      "timestamp": "2026-01-19T23:57:46.977762"
    },
    "drkg:Compound::DB00301": {
      "classification": "NOVEL",
      "evidence": "Flucloxacillin - Beta-lactam antibiotic for Gram-positive bacterial infections. No proven MS treatment role. Antibiotics not associated with MS risk. Source: DrugBank, PMC7152154",
      "timestamp": "2026-01-19T23:57:46.977763"
    },
    "drkg:Compound::DB12090": {
      "classification": "NOVEL",
      "evidence": "Patritumab - Anti-HER3 (ERBB3) monoclonal antibody for cancer. No MS connection. Source: DrugBank",
      "timestamp": "2026-01-19T23:57:46.977764"
    },
    "drkg:Compound::DB00355": {
      "classification": "NOVEL",
      "evidence": "Aztreonam - Monobactam antibiotic for Gram-negative infections. No MS treatment role. Source: DrugBank",
      "timestamp": "2026-01-19T23:57:46.977764"
    },
    "drkg:Compound::DB14012": {
      "classification": "NOVEL",
      "evidence": "Burosumab - Anti-FGF23 antibody for X-linked hypophosphatemia. No MS connection. Source: DrugBank",
      "timestamp": "2026-01-19T23:57:46.977765"
    },
    "drkg:Compound::DB12077": {
      "classification": "EXPERIMENTAL",
      "evidence": "Urelumab - Anti-CD137 (4-1BB) agonist antibody for cancer. CD137 essential for EAE development (MS model); CD137+ cells found in MS brain lesions; CD137L critical for EAE. Paradoxical - agonist may worsen MS. Source: J Neurosci 2012, PMC7677239",
      "timestamp": "2026-01-19T23:57:46.977765"
    },
    "drkg:Compound::DB14040": {
      "classification": "CONFIRMED",
      "evidence": "Eptinezumab - Anti-CGRP monoclonal antibody. FDA approved 2020 for migraine prevention. Study: 63% of MS patients with migraine had >75% reduction in migraine frequency. Safe in MS patients on DMTs. Source: PMC11096852, DrugBank",
      "timestamp": "2026-01-19T23:57:46.977766"
    },
    "drkg:Compound::DB13127": {
      "classification": "EXPERIMENTAL",
      "evidence": "Olokizumab - Anti-IL-6 humanized antibody for rheumatoid arthritis. IL-6 is recognized drug target for autoimmune diseases including MS. No specific MS clinical trials. Class mechanism relevance. Source: DrugBank, PubMed 26982101",
      "timestamp": "2026-01-19T23:57:46.977766"
    },
    "drkg:Compound::DB13406": {
      "classification": "CONFIRMED",
      "evidence": "First-generation sulfonylurea for Type 2 diabetes. First sulfonylurea marketed (1950s). Withdrawn due to bone marrow toxicity but was proven T2D treatment. Source: DrugBank, Wikipedia",
      "timestamp": "2026-01-20T00:08:46.504703"
    },
    "drkg:Compound::DB13951": {
      "classification": "NOVEL",
      "evidence": "Stanolone acetate (DHT acetate) - Androgen/anabolic steroid. Never marketed. No evidence for Type 2 diabetes treatment. Source: Wikipedia, DrugBank",
      "timestamp": "2026-01-20T05:21:18.961630"
    },
    "drkg:Compound::DB13629": {
      "classification": "NOVEL",
      "evidence": "Mofebutazone - NSAID for joint/muscular pain, rheumatic disorders. Introduced 1962. No evidence for diabetes treatment. Source: DrugBank, Wikipedia",
      "timestamp": "2026-01-20T05:21:18.961630"
    },
    "drkg:Compound::DB13544": {
      "classification": "NOVEL",
      "evidence": "Ethenzamide - NSAID with analgesic/antipyretic effects. Salicylic acid derivative for pain/inflammation. No diabetes indication. Source: DrugBank, PubMed 32147623",
      "timestamp": "2026-01-20T05:21:18.961630"
    },
    "drkg:Compound::DB12461": {
      "classification": "NOVEL",
      "evidence": "GLPG-0492 - JAK inhibitor for rheumatoid arthritis. No specific Type 2 diabetes trials or approval. Class has some diabetes research but not this specific drug. Source: Galapagos reports",
      "timestamp": "2026-01-20T05:21:18.961630"
    },
    "drkg:Compound::DB06788": {
      "classification": "NOVEL",
      "evidence": "Histrelin - GnRH agonist for precocious puberty/prostate cancer. FDA approved. Paradoxically INCREASES diabetes risk, not a diabetes treatment. Source: DrugBank, FDA warning",
      "timestamp": "2026-01-20T05:21:18.961630"
    },
    "drkg:Compound::DB12935": {
      "classification": "CONFIRMED",
      "evidence": "SGLT2 inhibitor. First global approval India 2019 for Type 2 diabetes. Reduces HbA1c by 0.5-1.0%. Source: PubMed 31201711, PMC7322139",
      "timestamp": "2026-01-20T00:08:46.504710"
    },
    "drkg:Compound::DB13347": {
      "classification": "NOVEL",
      "evidence": "Anticoagulant. No diabetes indication.",
      "timestamp": "2026-01-20T00:08:46.504711"
    },
    "drkg:Compound::DB13310": {
      "classification": "NOVEL",
      "evidence": "SERM contraceptive. No diabetes indication.",
      "timestamp": "2026-01-20T00:08:46.504711"
    },
    "drkg:Compound::DB12625": {
      "classification": "CONFIRMED",
      "evidence": "DPP-4 inhibitor. Approved South Korea October 2015 for Type 2 diabetes. Source: PubMed 26541763",
      "timestamp": "2026-01-20T00:08:46.504712"
    },
    "drkg:Compound::DB13233": {
      "classification": "NOVEL",
      "evidence": "SSRI antidepressant. No diabetes indication.",
      "timestamp": "2026-01-20T00:08:46.504712"
    },
    "drkg:Compound::DB13728": {
      "classification": "NOVEL",
      "evidence": "Corticosteroid. No diabetes indication.",
      "timestamp": "2026-01-20T00:08:46.504713"
    },
    "drkg:Compound::DB11491": {
      "classification": "NOVEL",
      "evidence": "Fluoroquinolone antibiotic. No diabetes indication.",
      "timestamp": "2026-01-20T00:08:46.504713"
    },
    "drkg:Compound::DB11577": {
      "classification": "NOVEL",
      "evidence": "Diagnostic dye. No diabetes indication.",
      "timestamp": "2026-01-20T00:08:46.504714"
    },
    "drkg:Compound::DB14600": {
      "classification": "NOVEL",
      "evidence": "Chelating agent. No diabetes indication.",
      "timestamp": "2026-01-20T00:08:46.504715"
    },
    "drkg:Compound::DB05830": {
      "classification": "NOVEL",
      "evidence": "Androgen hormone. No diabetes indication.",
      "timestamp": "2026-01-20T00:08:46.504715"
    },
    "drkg:Compound::DB09211": {
      "classification": "NOVEL",
      "evidence": "Prostaglandin E1. No diabetes indication.",
      "timestamp": "2026-01-20T00:08:46.504716"
    },
    "drkg:Compound::DB02123": {
      "classification": "NOVEL",
      "evidence": "Bile acid. No diabetes indication.",
      "timestamp": "2026-01-20T00:08:46.504716"
    },
    "drkg:Compound::DB13646": {
      "classification": "NOVEL",
      "evidence": "Thrombolytic agent. No diabetes indication.",
      "timestamp": "2026-01-20T00:08:46.504717"
    },
    "drkg:Compound::DB06127": {
      "classification": "CONFIRMED",
      "evidence": "DPP-IV inhibitor for Type 2 diabetes. Investigational Phase III trials. Source: DrugBank, NCBI",
      "timestamp": "2026-01-20T00:08:46.504717"
    },
    "drkg:Compound::DB12412": {
      "classification": "CONFIRMED",
      "evidence": "DPP-4 inhibitor. Approved Korea June 2012 for Type 2 diabetes. Source: PubMed 23771499",
      "timestamp": "2026-01-20T00:08:46.504718"
    },
    "drkg:Compound::DB12268": {
      "classification": "CONFIRMED",
      "evidence": "DPP-4 inhibitor selected for clinical development for Type 2 diabetes. Investigational. Source: PubMed 20031405",
      "timestamp": "2026-01-20T00:08:46.504718"
    },
    "drkg:Compound::DB09043": {
      "classification": "CONFIRMED",
      "evidence": "GLP-1 receptor agonist. FDA approved April 2014 for Type 2 diabetes. Withdrawn 2017. Source: DrugBank, PMC4665069",
      "timestamp": "2026-01-20T00:08:46.504719"
    },
    "drkg:Compound::DB11691": {
      "classification": "NOVEL",
      "evidence": "Naldemedine - Peripherally acting mu-opioid receptor antagonist. FDA approved for opioid-induced constipation in adults. Not a diabetes treatment. Source: DrugBank, FDA label",
      "timestamp": "2026-01-20T00:12:30.456911"
    },
    "drkg:Compound::DB14633": {
      "classification": "NOVEL",
      "evidence": "Prednisolone hemisuccinate - Corticosteroid. Glucocorticoids CAUSE diabetes/hyperglycemia (12-18.6% incidence), not treat it. Meta-analysis showed 32.3% hyperglycemia rate. Source: PMC9142341, Nature Rev Endo 2022",
      "timestamp": "2026-01-20T00:12:30.456914"
    },
    "drkg:Compound::DB01700": {
      "classification": "EXPERIMENTAL",
      "evidence": "AICA ribonucleotide (AICAR) - AMPK activator. Clinical trials in Type 2 diabetes patients showed IV AICAR reduces hepatic glucose output and lowers blood glucose. Improves insulin sensitivity in preclinical models. Source: PubMed 18709353, Diabetes 2002",
      "timestamp": "2026-01-20T00:12:30.456915"
    },
    "drkg:Compound::DB13166": {
      "classification": "NOVEL",
      "evidence": "Zofenopril - ACE inhibitor for hypertension. Used in diabetic patients for cardiovascular protection and diabetic nephropathy, but not a direct diabetes treatment. Source: PMC2686259, DrugBank",
      "timestamp": "2026-01-20T00:12:30.456916"
    },
    "drkg:Compound::DB12771": {
      "classification": "NOVEL",
      "evidence": "Hydroxytyrosol - Olive oil polyphenol. Preclinical studies show improved glucose tolerance and insulin sensitivity in diabetic rats, but no clinical trials for diabetes treatment. Dietary compound, not approved drug. Source: ScienceDirect 2024, J Transl Med 2014",
      "timestamp": "2026-01-20T00:12:30.456916"
    },
    "drkg:Compound::DB02060": {
      "classification": "NOVEL",
      "evidence": "Ketohexamethylene - Experimental chemical compound. No evidence as pharmaceutical drug or obesity treatment. Source: DrugBank",
      "timestamp": "2026-01-20T05:23:15.037147"
    },
    "drkg:Compound::DB12798": {
      "classification": "NOVEL",
      "evidence": "Relenopride (YKP-10811) - 5-HT4 receptor agonist for chronic constipation. Phase II trials for constipation/IBS. No obesity indication. Source: DrugBank, PMC3108672",
      "timestamp": "2026-01-20T05:23:15.037147"
    },
    "drkg:Compound::DB08591": {
      "classification": "NOVEL",
      "evidence": "Experimental thiadiazolidinone compound. No evidence as pharmaceutical drug or obesity treatment. Source: DrugBank",
      "timestamp": "2026-01-20T05:24:27.215147"
    },
    "drkg:Compound::DB08369": {
      "classification": "NOVEL",
      "evidence": "Experimental imidazole compound. No evidence as pharmaceutical drug or obesity treatment. Source: DrugBank",
      "timestamp": "2026-01-20T05:24:27.215147"
    },
    "drkg:Compound::DB02846": {
      "classification": "NOVEL",
      "evidence": "L-thioproline - Amino acid analog/derivative. Experimental compound. No evidence as obesity treatment. Source: DrugBank",
      "timestamp": "2026-01-20T05:24:27.215147"
    },
    "drkg:Compound::DB08546": {
      "classification": "NOVEL",
      "evidence": "Experimental pyrrolizidine compound. No evidence as pharmaceutical drug or obesity treatment. Source: DrugBank",
      "timestamp": "2026-01-20T05:24:27.215147"
    },
    "drkg:Compound::DB08109": {
      "classification": "NOVEL",
      "evidence": "(1S,4R,7AR)-4-BUTOXY compound - Complex experimental compound, no asthma indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:28:19.441423"
    },
    "drkg:Compound::DB12529": {
      "classification": "EXPERIMENTAL",
      "evidence": "Nitrite (sodium nitrite) - Investigated for asthma bronchodilation. Pilot trial showed nebulized sodium nitrite is safe in asthmatic patients with potential to reduce exacerbations. Nitroglycerin produces moderate bronchodilation. Source: PMC3658695, ScienceDirect S1094553920301899",
      "timestamp": "2026-01-20T05:28:19.441424"
    },
    "drkg:Compound::DB04422": {
      "classification": "NOVEL",
      "evidence": "L-Homocysteine - Amino acid metabolite, no asthma treatment indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:28:19.441424"
    },
    "drkg:Compound::DB14519": {
      "classification": "NOVEL",
      "evidence": "Aluminum cation - Metal ion, no specific asthma treatment indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:28:19.441425"
    },
    "drkg:Compound::DB08375": {
      "classification": "NOVEL",
      "evidence": "(2R)-2-[(1R)-1-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)...] - Beta-lactam-like structure, no asthma indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:28:19.441426"
    },
    "drkg:Compound::DB04492": {
      "classification": "NOVEL",
      "evidence": "N-Acetylglucosamine 4-sulfate - Metabolite, no asthma treatment indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:28:19.441427"
    },
    "drkg:Compound::DB00417": {
      "classification": "NOVEL",
      "evidence": "Penicillin V - Beta-lactam antibiotic for bacterial infections. GINA 2018 states antibiotics should not be routinely prescribed for asthma exacerbations. Macrolides preferred when needed, not penicillins. Source: PMC7126415, Cochrane",
      "timestamp": "2026-01-20T05:28:19.441428"
    },
    "drkg:Compound::DB15097": {
      "classification": "CONFIRMED",
      "evidence": "Gefapixant - P2X3 receptor antagonist. FDA approved for refractory chronic cough and unexplained chronic cough. Chronic cough often associated with asthma. Phase 3 trials (COUGH-1, COUGH-2) showed 14-18% reduction in 24h cough frequency. Source: Lancet, PMC10487696",
      "timestamp": "2026-01-20T05:28:19.441428"
    },
    "drkg:Compound::DB05100": {
      "classification": "EXPERIMENTAL",
      "evidence": "Prinomastat - MMP inhibitor tested in cancer. MMPs involved in chronic airway remodeling in asthma/COPD. MMP-9 inhibition discussed as treatment perspective. Limited study in asthma reflects difficulty measuring chronic remodeling outcomes. Source: Springer, ERJ",
      "timestamp": "2026-01-20T05:28:19.441429"
    },
    "drkg:Compound::DB08834": {
      "classification": "EXPERIMENTAL",
      "evidence": "Tauroursodeoxycholic acid (TUDCA) - Bile acid with anti-inflammatory effects. Phase clinical trial NCT03878654 for asthma (12 patients, 12 weeks). Preclinical: CBAs like TUDCA decrease inflammatory responses, mucus metaplasia, airway hyperresponsiveness by inhibiting UPR transducers. Source: JCI Insight, ClinicalTrials.gov",
      "timestamp": "2026-01-20T05:28:19.441430"
    },
    "drkg:Compound::DB13029": {
      "classification": "EXPERIMENTAL",
      "evidence": "MK-0873 - Selective PDE4 inhibitor developed for COPD. Preclinical: potent dose-dependent inhibition of antigen-induced bronchoconstriction in guinea pigs, protected against early/late-phase response in Ascaris-sensitive sheep. Safe in Phase I trials up to 4mg for 28 days. Also developed for topical psoriasis. Source: MedChemExpress, PubMed 18321743",
      "timestamp": "2026-01-20T05:29:49.293190"
    },
    "drkg:Compound::DB11861": {
      "classification": "NOVEL",
      "evidence": "Litronesib (LY2523355) - Selective kinesin Eg5 inhibitor for cancer. Mitotic arrest mechanism irrelevant to asthma. Tested in solid tumors, ovarian, gastric, prostate cancer. No respiratory/asthma connection. Source: Springer, DrugBank",
      "timestamp": "2026-01-20T05:29:49.293193"
    },
    "drkg:Compound::DB04728": {
      "classification": "NOVEL",
      "evidence": "lividomycin A - Aminoglycoside antibiotic similar to neomycin. No asthma treatment role. Source: DrugBank",
      "timestamp": "2026-01-20T05:29:49.293195"
    },
    "drkg:Compound::DB14151": {
      "classification": "NOVEL",
      "evidence": "phosphane - Simple inorganic compound (PH3), no pharmaceutical/asthma indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:29:49.293196"
    },
    "drkg:Compound::DB01906": {
      "classification": "NOVEL",
      "evidence": "3-(5-amino-7-hydroxy-(1,2,3)triazolo(4,5-d)pyrimidin-2-yl)benzoic acid - Experimental compound, no asthma indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:29:49.293197"
    },
    "drkg:Compound::DB11597": {
      "classification": "NOVEL",
      "evidence": "DB11597 - No specific drug name or information available. No asthma connection found. Source: DrugBank",
      "timestamp": "2026-01-20T05:29:49.293197"
    },
    "drkg:Compound::DB03530": {
      "classification": "NOVEL",
      "evidence": "(2R)-2-[(1R)-1-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)...] - Beta-lactam antibiotic derivative, no asthma indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:29:49.293198"
    },
    "drkg:Compound::DB12290": {
      "classification": "EXPERIMENTAL",
      "evidence": "Puerarin - Isoflavone from Pueraria lobata (Kudzu root), traditional Chinese medicine. Preclinical: significantly reduced eosinophils, IL-4/5/13, IgE, eotaxin-3 in OVA-induced asthma mice models. Inhibits Th2, enhances Th1 response. Prevents allergic airway inflammation in rodents. Source: PubMed 24523826, Wiley ECAM 2014",
      "timestamp": "2026-01-20T05:29:49.293198"
    },
    "drkg:Compound::DB07493": {
      "classification": "EXPERIMENTAL",
      "evidence": "5-Bromoindirubin - Kinase inhibitor derivative. 5-Bromo indirubin derivatives suppress pro-inflammatory cytokine/prostaglandin release in LPS-stimulated human monocytes. GSK-3\u03b2 inhibitors significantly reduce OVA-induced airway inflammation in asthma mice models. Class mechanism relevant to allergic airway inflammation. Source: PubMed 28743492, Nature s41598-017-11662-7",
      "timestamp": "2026-01-20T05:30:58.588640"
    },
    "drkg:Compound::DB03834": {
      "classification": "NOVEL",
      "evidence": "TAZOBACTAM INTERMEDIATE - Intermediate compound in tazobactam synthesis. Tazobactam is beta-lactamase inhibitor for respiratory infections (pneumonia), not asthma treatment. Source: DrugBank, NCBI Bookshelf",
      "timestamp": "2026-01-20T05:30:58.588643"
    },
    "drkg:Compound::DB08069": {
      "classification": "NOVEL",
      "evidence": "4-amino-5-(2-methylphenyl)-4H-1,2,4-triazole-3-thiol - Experimental triazole compound, no asthma indication found. Source: DrugBank",
      "timestamp": "2026-01-20T05:30:58.588643"
    },
    "drkg:Compound::DB09062": {
      "classification": "NOVEL",
      "evidence": "Cefminox - Second-generation cephalosporin antibiotic for bacterial infections. Not a COPD maintenance treatment. May treat acute bacterial exacerbations but not indicated for COPD itself. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:16.349823"
    },
    "drkg:Compound::DB01274": {
      "classification": "CONFIRMED",
      "evidence": "Arformoterol tartrate (BROVANA) - FDA approved long-acting beta2-agonist (LABA) for twice-daily maintenance treatment of bronchoconstriction in COPD (chronic bronchitis/emphysema). (R,R)-formoterol enantiomer administered 15\u00b5g by nebulizer. Significantly improves FEV1, dyspnea, exacerbation rate. Source: PMC2629977, FDA Label",
      "timestamp": "2026-01-20T05:32:16.349826"
    },
    "drkg:Compound::DB00983": {
      "classification": "CONFIRMED",
      "evidence": "Formoterol - FDA approved twice-daily LABA for COPD. Significantly improves FEV1, lung volumes, dyspnea, exacerbation rate, hospitalizations. Administered via inhaler/nebulizer. Source: Wikipedia, NCBI Bookshelf NBK519028",
      "timestamp": "2026-01-20T05:32:16.349827"
    },
    "drkg:Compound::DB00860": {
      "classification": "CONFIRMED",
      "evidence": "Prednisolone - Corticosteroid used for COPD exacerbations. Reduces inflammation, improves symptoms during acute exacerbations. Standard treatment for COPD flares. Source: NCBI Bookshelf, clinical guidelines",
      "timestamp": "2026-01-20T05:32:16.349828"
    },
    "drkg:Compound::DB05039": {
      "classification": "CONFIRMED",
      "evidence": "Indacaterol (ARCAPTA NEOHALER) - FDA approved July 2011 as first once-daily ultra-LABA for COPD maintenance. Rapid onset (5 min) with 24h effect. 75\u00b5g dose approved. Superior to formoterol/salmeterol in clinical studies. Source: PMC3728154, FDA 2011",
      "timestamp": "2026-01-20T05:32:16.349829"
    },
    "drkg:Compound::DB12833": {
      "classification": "NOVEL",
      "evidence": "Tandospirone - 5-HT1A receptor agonist anxiolytic for anxiety disorders. No COPD indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:16.349829"
    },
    "drkg:Compound::DB11543": {
      "classification": "NOVEL",
      "evidence": "Romifidine - Alpha-2 adrenergic agonist used in veterinary medicine for sedation. No human COPD indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:16.349831"
    },
    "drkg:Compound::DB12712": {
      "classification": "NOVEL",
      "evidence": "Pilsicainide - Class Ic antiarrhythmic for ventricular arrhythmias. No COPD indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:16.349831"
    },
    "drkg:Compound::DB01062": {
      "classification": "NOVEL",
      "evidence": "Oxybutynin - Anticholinergic for overactive bladder, not pulmonary use. No COPD indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:59.267201"
    },
    "drkg:Compound::DB13170": {
      "classification": "NOVEL",
      "evidence": "Plecanatide - Guanylate cyclase-C agonist for chronic constipation/IBS-C. No COPD indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:59.267204"
    },
    "drkg:Compound::DB07549": {
      "classification": "NOVEL",
      "evidence": "Complex pyrazine compound - Experimental molecule, no COPD indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:59.267206"
    },
    "drkg:Compound::DB12923": {
      "classification": "NOVEL",
      "evidence": "Gallopamil - Calcium channel blocker for cardiac conditions. No COPD indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:59.267207"
    },
    "drkg:Compound::DB13500": {
      "classification": "NOVEL",
      "evidence": "Otilonium - Antispasmodic for IBS. No COPD indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:59.267208"
    },
    "drkg:Compound::DB09290": {
      "classification": "NOVEL",
      "evidence": "Ramosetron - 5-HT3 antagonist for IBS. No COPD indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:59.267209"
    },
    "drkg:Compound::DB08099": {
      "classification": "NOVEL",
      "evidence": "Tetrahydroquinoline compound - Experimental molecule, no COPD indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:59.267210"
    },
    "drkg:Compound::DB13217": {
      "classification": "NOVEL",
      "evidence": "Fentiazac - NSAID for pain/inflammation. No specific COPD treatment indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:59.267210"
    },
    "drkg:Compound::DB11338": {
      "classification": "NOVEL",
      "evidence": "Clove oil - Natural product for dental pain. No COPD treatment indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:59.267211"
    },
    "drkg:Compound::DB06708": {
      "classification": "NOVEL",
      "evidence": "Lumefantrine - Antimalarial combined with artemether. No COPD indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:59.267211"
    },
    "drkg:Compound::DB13860": {
      "classification": "NOVEL",
      "evidence": "Imidazole salicylate - Topical analgesic. No COPD indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:32:59.267212"
    },
    "drkg:Compound::DB00207": {
      "classification": "EXPERIMENTAL",
      "evidence": "Azithromycin - Macrolide antibiotic. Chronic 250mg daily reduces COPD exacerbations (median time to first: 266 vs 174 days placebo). Guidelines suggest for severe COPD with frequent exacerbations despite optimal inhaled therapy. Greater efficacy in older patients, past smokers. Concerns: hearing loss, macrolide resistance, cardiac risk. Source: NEJM 2011, PMC3186743",
      "timestamp": "2026-01-20T05:33:44.528087"
    },
    "drkg:Compound::DB06764": {
      "classification": "NOVEL",
      "evidence": "Tetryzoline - Alpha-adrenergic agonist nasal decongestant/eye drops. No COPD treatment indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:33:44.528090"
    },
    "drkg:Compound::DB09252": {
      "classification": "NOVEL",
      "evidence": "Pivhydrazine - MAO inhibitor antidepressant. No COPD indication. Source: DrugBank",
      "timestamp": "2026-01-20T05:33:44.528091"
    },
    "drkg:Compound::DB09273": {
      "classification": "CONFIRMED",
      "evidence": "Doxofylline - Methylxanthine bronchodilator approved for COPD, asthma, bronchospasm. Similar efficacy to theophylline but better safety profile (less cardiac/CNS effects, no drug interactions, no TDM needed). Delays pulmonary function decline, reduces exacerbations (13-16% reduction). Source: DrugBank, PMC5723117, PMC10500324",
      "timestamp": "2026-01-20T05:33:44.528092"
    },
    "drkg:Compound::DB00561": {
      "classification": "EXPERIMENTAL",
      "evidence": "Doxapram - Respiratory stimulant for acute respiratory insufficiency in COPD. FDA approved for hospitalized patients with acute exacerbations to prevent CO2 elevation during oxygen therapy. Stimulates carotid chemoreceptors. Short-term use only, improves blood gases marginally vs placebo. Source: DrugBank, NEJM 1973, Cochrane",
      "timestamp": "2026-01-20T05:33:44.528092"
    },
    "drkg:Compound::DB13020": {
      "classification": "EXPERIMENTAL",
      "evidence": "Apratastat (TMI-005) - MMP/TACE inhibitor. Phase II trial for rheumatoid arthritis failed (lack of efficacy). MMPs involved in bone resorption; MMP inhibitors studied for osteoporosis but apratastat terminated. Source: PubMed 17117591, DrugBank",
      "timestamp": "2026-01-20T13:37:05.112595"
    },
    "drkg:Compound::DB07149": {
      "classification": "NOVEL",
      "evidence": "(7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one - Research compound, no drug development or clinical use. Source: DrugBank",
      "timestamp": "2026-01-20T13:37:05.112603"
    },
    "drkg:Compound::DB14845": {
      "classification": "EXPERIMENTAL",
      "evidence": "Filgotinib - JAK1 inhibitor. FDA approved for rheumatoid arthritis/ulcerative colitis. JAK inhibitors increase bone mass in preclinical models, suppress bone resorption, allow bone erosion repair in RA. No specific osteoporosis trials. Source: BMC Inflamm Regen 2023, PubMed 32051226",
      "timestamp": "2026-01-20T13:37:05.112610"
    },
    "drkg:Compound::DB05047": {
      "classification": "NOVEL",
      "evidence": "CX717 - AMPA receptor positive allosteric modulator (ampakine) for cognitive enhancement. Studied for ADHD, Alzheimer's, sleep deprivation. No bone or osteoporosis indication. Source: Wikipedia, PubMed 21940760",
      "timestamp": "2026-01-20T13:37:05.112613"
    },
    "drkg:Compound::DB09151": {
      "classification": "NOVEL",
      "evidence": "Flutemetamol (18F) (Vizamyl) - PET imaging agent for brain amyloid plaques in Alzheimer's disease. FDA approved 2013. Used for brain imaging only, not bone imaging. Source: FDA, Wikipedia",
      "timestamp": "2026-01-20T13:37:05.112615"
    }
  },
  "enhanced_gt": {
    "Colorectal cancer": [
      {
        "drug_id": "drkg:Compound::DB14935",
        "db_id": "DB14935",
        "name": "Serabelisib",
        "classification": "EXPERIMENTAL",
        "evidence": "Serabelisib (TAK-117) - PI3K-alpha inhibitor. Phase I/II trials (NCT05300048, NCT04073680) for advanced solid tumors with PIK3CA mutations including CRC expansion cohort. Source: ClinicalTrials.gov, MDPI",
        "model_score": 0.9585772185110751
      }
    ],
    "HIV infection": [
      {
        "drug_id": "drkg:Compound::DB06619",
        "db_id": "DB06619",
        "name": "Amdoxovir",
        "classification": "CONFIRMED",
        "evidence": "Investigational NRTI for HIV. Phase II trials conducted (NCT01737359, NCT00432016). Development discontinued ~2010 but was a real HIV drug candidate. Source: NIH AIDSinfo",
        "model_score": 0.9981
      },
      {
        "drug_id": "drkg:Compound::DB02883",
        "db_id": "DB02883",
        "name": "5'-Cytidylic acid, 2',3'-dideoxy- (Zalcitabine/ddC precursor)",
        "classification": "CONFIRMED",
        "evidence": "Zalcitabine (ddC) was FDA approved 1992 as 3rd antiretroviral. NRTI class. Discontinued 2005 due to toxicity but was proven HIV treatment. Source: Wikipedia, NIH",
        "model_score": 0.9903
      }
    ],
    "Lung cancer": [
      {
        "drug_id": "drkg:Compound::DB12410",
        "db_id": "DB12410",
        "name": "Sabarubicin",
        "classification": "EXPERIMENTAL",
        "evidence": "Sabarubicin (MEN 10755) - Disaccaride anthracycline tested in Phase II trials for lung cancer. Preclinical studies showed antitumour effect in NSCLC H460 and SCLC GLC4 combined with cisplatin. Clinical trials were ongoing as of 2007-2008. Source: PubMed 18038274, Springer",
        "model_score": 0.9973138836327089
      },
      {
        "drug_id": "drkg:Compound::DB11747",
        "db_id": "DB11747",
        "name": "Barasertib",
        "classification": "EXPERIMENTAL",
        "evidence": "AZD1152 - Aurora B kinase inhibitor. Phase II trials in small-cell lung cancer, Phase I in advanced solid tumors (23% stable disease, no objective responses, MTD 150-220mg). Showed tumor regression in SCLC xenografts at 100mg/kg. Source: AACR, PubMed 27496133",
        "model_score": 0.9717053084139391
      }
    ],
    "Hypertension": [
      {
        "drug_id": "drkg:Compound::DB07467",
        "db_id": "DB07467",
        "name": "(S)-Indapamide",
        "classification": "CONFIRMED",
        "evidence": "(S)-Indapamide - Indapamide is FDA-approved thiazide-like diuretic for hypertension since 1983. Used as sole treatment or with other antihypertensives. Source: FDA, NCBI Bookshelf, Wikipedia",
        "model_score": 0.9764325228348425
      }
    ],
    "Heart failure": [
      {
        "drug_id": "drkg:Compound::DB06231",
        "db_id": "DB06231",
        "name": "Caldaret",
        "classification": "EXPERIMENTAL",
        "evidence": "Caldaret - Intracellular Ca2+ handling modulator. Phase II CASTEMI trial for ST-elevation myocardial infarction undergoing primary PCI. Investigated for heart disease and myocardial infarction. Trial showed no benefit vs placebo for infarct size; CHF by 30 days was 15.7% placebo vs 21.6% low dose. Source: ACC, PubMed 17299242",
        "model_score": 0.9886372784490094
      },
      {
        "drug_id": "drkg:Compound::DB15112",
        "db_id": "DB15112",
        "name": "Somatropin pegol",
        "classification": "EXPERIMENTAL",
        "evidence": "Somatropin pegol (NNC126-0083) - PEGylated growth hormone investigated in trial NCT00715689 for GH deficiency. Some evidence that GH therapy improves hemodynamics in HF patients, but this specific drug is in early trials for GHD. Source: NCATS, PubMed 15981951",
        "model_score": 0.9854432229920805
      }
    ]
  },
  "research_log": [
    {
      "disease": "HIV infection",
      "drug": "Amdoxovir",
      "classification": "CONFIRMED",
      "timestamp": "2026-01-19T22:09:45.130103"
    },
    {
      "disease": "HIV infection",
      "drug": "5'-Cytidylic acid, 2',3'-dideoxy- (Zalcitabine/ddC precursor)",
      "classification": "CONFIRMED",
      "timestamp": "2026-01-19T22:09:45.130106"
    },
    {
      "disease": "HIV infection",
      "drug": "Tegobuvir",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:09:45.130108"
    },
    {
      "disease": "HIV infection",
      "drug": "miransertib",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:13:37.801803"
    },
    {
      "disease": "HIV infection",
      "drug": "Difelikefalin",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:13:37.801806"
    },
    {
      "disease": "HIV infection",
      "drug": "Stannsoporfin",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:13:37.801808"
    },
    {
      "disease": "HIV infection",
      "drug": "5'-Cytidylic acid, 2',3'-dideoxy- (Zalcitabine/ddC)",
      "classification": "CONFIRMED",
      "timestamp": "2026-01-19T22:15:36.036485"
    },
    {
      "disease": "HIV infection",
      "drug": "DB15019",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:00:00.000000"
    },
    {
      "disease": "HIV infection",
      "drug": "3'-Phosphate-Adenosine-5'-Diphosphate",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:00:00.000001"
    },
    {
      "disease": "HIV infection",
      "drug": "Dimethyldioctadecylammonium",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:00:00.000002"
    },
    {
      "disease": "HIV infection",
      "drug": "Efmoroctocog alfa",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:00:00.000003"
    },
    {
      "disease": "HIV infection",
      "drug": "MLN8054",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:00:00.000004"
    },
    {
      "disease": "HIV infection",
      "drug": "ADL5859",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:00:00.000005"
    },
    {
      "disease": "HIV infection",
      "drug": "Zopolrestat",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:00:00.000006"
    },
    {
      "disease": "HIV infection",
      "drug": "Ethyl Isocyanide",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:00:00.000007"
    },
    {
      "disease": "Hepatitis C",
      "drug": "Adefovir Dipivoxil",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:54:13.052014"
    },
    {
      "disease": "Hepatitis C",
      "drug": "Camicinal",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:54:13.052015"
    },
    {
      "disease": "Hepatitis C",
      "drug": "Benzylpenicillin",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:54:13.052016"
    },
    {
      "disease": "Hepatitis C",
      "drug": "Methotrexate",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:54:13.052017"
    },
    {
      "disease": "Hepatitis C",
      "drug": "Chlorambucil",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:54:13.052018"
    },
    {
      "disease": "Hepatitis C",
      "drug": "Bedoradrine",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:54:13.052018"
    },
    {
      "disease": "Hepatitis C",
      "drug": "Raxatrigine",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:54:13.052019"
    },
    {
      "disease": "Hepatitis C",
      "drug": "CYT007-TNFQb",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:54:13.052020"
    },
    {
      "disease": "Hepatitis C",
      "drug": "Urea-14C",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:54:13.052021"
    },
    {
      "disease": "Hepatitis C",
      "drug": "Coproporphyrin I",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:54:13.052021"
    },
    {
      "disease": "Tuberculosis",
      "drug": "5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:59:19.284694"
    },
    {
      "disease": "Tuberculosis",
      "drug": "N-[4-(4-nitrophenylphospho)butanoyl]-L-alanine",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:59:19.284695"
    },
    {
      "disease": "Tuberculosis",
      "drug": "PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-[(PYRIDIN-3-YLMETHYL)-AMIDE]",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:59:19.284695"
    },
    {
      "disease": "Tuberculosis",
      "drug": "PF-03758309",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:59:19.284696"
    },
    {
      "disease": "Tuberculosis",
      "drug": "Coproporphyrin I",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:59:19.284697"
    },
    {
      "disease": "Tuberculosis",
      "drug": "3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:59:19.284697"
    },
    {
      "disease": "Tuberculosis",
      "drug": "4-(4-STYRYL-PHENYLCARBAMOYL)-BUTYRIC ACID",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:59:19.284698"
    },
    {
      "disease": "Tuberculosis",
      "drug": "GW-406381",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:59:19.284698"
    },
    {
      "disease": "Tuberculosis",
      "drug": "N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:59:19.284699"
    },
    {
      "disease": "Tuberculosis",
      "drug": "Pexacerfont (DPC-related compound)",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T22:59:19.284700"
    },
    {
      "disease": "Tuberculosis",
      "drug": "FR236913",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:01:19.528576"
    },
    {
      "disease": "Tuberculosis",
      "drug": "Adefovir Dipivoxil",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:01:19.528577"
    },
    {
      "disease": "Tuberculosis",
      "drug": "Zimlovisertib",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:01:19.528577"
    },
    {
      "disease": "Tuberculosis",
      "drug": "Zalcitabine (for TB)",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:01:19.528578"
    },
    {
      "disease": "Tuberculosis",
      "drug": "trans-Zeatin",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:01:19.528578"
    },
    {
      "disease": "Breast cancer",
      "drug": "4-(4-STYRYL-PHENYLCARBAMOYL)-BUTYRIC ACID",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    {
      "disease": "Breast cancer",
      "drug": "Selitrectinib",
      "classification": "EXPERIMENTAL",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    {
      "disease": "Breast cancer",
      "drug": "Belimumab",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    {
      "disease": "Breast cancer",
      "drug": "Demeclocycline",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    {
      "disease": "Breast cancer",
      "drug": "2,3-DIMETHOXY-12H-[1,3]DIOXOLO[5,6]INDENO[1,2-C]ISOQUINOLIN-6-IUM",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    {
      "disease": "Breast cancer",
      "drug": "Larotaxel",
      "classification": "EXPERIMENTAL",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    {
      "disease": "Breast cancer",
      "drug": "Apatorsen",
      "classification": "EXPERIMENTAL",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    {
      "disease": "Breast cancer",
      "drug": "2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    {
      "disease": "Breast cancer",
      "drug": "2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    {
      "disease": "Breast cancer",
      "drug": "Lorvotuzumab mertansine",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:03:57.515891"
    },
    {
      "disease": "Breast cancer",
      "drug": "Influenza A virus vaccine",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    {
      "disease": "Breast cancer",
      "drug": "beta-Isosparteine",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    {
      "disease": "Breast cancer",
      "drug": "Zeranol",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    {
      "disease": "Breast cancer",
      "drug": "(2-AMINO-3-PHENYL-BICYCLO[2.2.1]HEPT-2-YL)-PHENYL-METHANONE",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    {
      "disease": "Breast cancer",
      "drug": "Piromelatine",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    {
      "disease": "Breast cancer",
      "drug": "N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    {
      "disease": "Breast cancer",
      "drug": "Salicylate-sodium",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    {
      "disease": "Breast cancer",
      "drug": "Cisplatin",
      "classification": "EXPERIMENTAL",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    {
      "disease": "Breast cancer",
      "drug": "Sabarubicin",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    {
      "disease": "Breast cancer",
      "drug": "Fruquintinib",
      "classification": "EXPERIMENTAL",
      "timestamp": "2026-01-19T23:05:17.487553"
    },
    {
      "disease": "Lung cancer",
      "drug": "Sabarubicin",
      "classification": "EXPERIMENTAL",
      "timestamp": "2026-01-19T23:08:07.907709"
    },
    {
      "disease": "Lung cancer",
      "drug": "N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:08:07.907709"
    },
    {
      "disease": "Lung cancer",
      "drug": "3-(5-methoxy-1H-indol-3-yl)propanoic acid",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:08:07.907709"
    },
    {
      "disease": "Lung cancer",
      "drug": "4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:08:07.907709"
    },
    {
      "disease": "Lung cancer",
      "drug": "1,3-Dinitrobenzene",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:08:07.907709"
    },
    {
      "disease": "Lung cancer",
      "drug": "Daprodustat",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:08:07.907709"
    },
    {
      "disease": "Lung cancer",
      "drug": "Barasertib",
      "classification": "EXPERIMENTAL",
      "timestamp": "2026-01-19T23:08:07.907709"
    },
    {
      "disease": "Lung cancer",
      "drug": "SUVN-502",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:08:07.907709"
    },
    {
      "disease": "Lung cancer",
      "drug": "Loxicodegol",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:08:07.907709"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "(4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:15:00.000000"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "3'-Phosphate-Adenosine-5'-Diphosphate",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:15:00.000000"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "4-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:15:00.000001"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOXAZIN-4-YL]ETHYL}ACETAMIDE",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:15:00.000002"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:15:00.000002"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:15:00.000003"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "Ethyl Isocyanide",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:15:00.000003"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "1,2-dichloroethane",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:15:00.000004"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "KD3010",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:15:00.000005"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "ND7001",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:15:00.000006"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:15:00.000007"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "trifluoro-[hydroxy-[hydroxy-[2-(N-methyl-2-nitro-anilino)ethoxy]phosphoryl]oxy-phosphoryl]oxy-beryllium(1-)",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:15:00.000008"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "[(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:15:00.000009"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "Foreskin keratinocyte (neonatal)",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:15:00.000010"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "Serabelisib",
      "classification": "EXPERIMENTAL",
      "timestamp": "2026-01-19T23:15:00.000011"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "DB02472",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:30:00.000000"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "DB06977",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:30:00.000001"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "DB07146",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:30:00.000002"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "DB08200",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:30:00.000003"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "DB07088",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:30:00.000004"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "DB03359",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:30:00.000005"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "DB02112",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:30:00.000006"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "DB08148",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:30:00.000007"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "DB03759",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:30:00.000008"
    },
    {
      "disease": "Colorectal cancer",
      "drug": "DB03376",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:30:00.000009"
    },
    {
      "disease": "Hypertension",
      "drug": "DB07467",
      "classification": "CONFIRMED",
      "timestamp": "2026-01-19T23:17:55.247641"
    },
    {
      "disease": "Hypertension",
      "drug": "DB00502",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:17:55.247644"
    },
    {
      "disease": "Hypertension",
      "drug": "DB00901",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:17:55.247645"
    },
    {
      "disease": "Hypertension",
      "drug": "DB00320",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:17:55.247646"
    },
    {
      "disease": "Hypertension",
      "drug": "DB00532",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:17:55.247646"
    },
    {
      "disease": "Hypertension",
      "drug": "DB05070",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:17:55.247647"
    },
    {
      "disease": "Hypertension",
      "drug": "DB13908",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:17:55.247647"
    },
    {
      "disease": "Hypertension",
      "drug": "DB12149",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:17:55.247648"
    },
    {
      "disease": "Hypertension",
      "drug": "DB12608",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:17:55.247648"
    },
    {
      "disease": "Hypertension",
      "drug": "DB12067",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:17:55.247649"
    },
    {
      "disease": "Heart failure",
      "drug": "Amdoxovir",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724592"
    },
    {
      "disease": "Heart failure",
      "drug": "N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724593"
    },
    {
      "disease": "Heart failure",
      "drug": "DB15019",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724594"
    },
    {
      "disease": "Heart failure",
      "drug": "Caldaret",
      "classification": "EXPERIMENTAL",
      "timestamp": "2026-01-19T23:20:50.724594"
    },
    {
      "disease": "Heart failure",
      "drug": "Dimethyldioctadecylammonium",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724595"
    },
    {
      "disease": "Heart failure",
      "drug": "(R)-tacrine(10)-hupyridone",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724595"
    },
    {
      "disease": "Heart failure",
      "drug": "4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724596"
    },
    {
      "disease": "Heart failure",
      "drug": "benzyl-indol-phosphonic acid",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724596"
    },
    {
      "disease": "Heart failure",
      "drug": "N-ETHYL-N-ISOPROPYL benzamide",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724597"
    },
    {
      "disease": "Heart failure",
      "drug": "(1R)-menthyl hexyl phosphonate",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724597"
    },
    {
      "disease": "Heart failure",
      "drug": "Poa compressa pollen",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724598"
    },
    {
      "disease": "Heart failure",
      "drug": "1,4-Dideoxy-O2-Sulfo-Glucuronic Acid",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724598"
    },
    {
      "disease": "Heart failure",
      "drug": "beta-L-fructofuranose",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724599"
    },
    {
      "disease": "Heart failure",
      "drug": "Somatropin pegol",
      "classification": "EXPERIMENTAL",
      "timestamp": "2026-01-19T23:20:50.724599"
    },
    {
      "disease": "Heart failure",
      "drug": "cyclohexyl-pyrrolidine benzylamide",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724600"
    },
    {
      "disease": "Heart failure",
      "drug": "Difelikefalin",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724600"
    },
    {
      "disease": "Heart failure",
      "drug": "2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724601"
    },
    {
      "disease": "Heart failure",
      "drug": "beryllium phosphonate",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724601"
    },
    {
      "disease": "Heart failure",
      "drug": "Efmoroctocog alfa",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724602"
    },
    {
      "disease": "Heart failure",
      "drug": "chloro-ethoxy-benzamide",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724603"
    },
    {
      "disease": "Heart failure",
      "drug": "Tegobuvir",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724603"
    },
    {
      "disease": "Heart failure",
      "drug": "Amylmetacresol",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:20:50.724604"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "PYRIMIDINE-4,6-DICARBOXYLIC ACID BIS-[(PYRIDIN-3-YLMETHYL)-AMIDE]",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:00:00.000000"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "3-dehydroquinic acid",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:00:00.000001"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "(2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:00:00.000002"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "2-Chlorophenol",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:00:00.000003"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:00:00.000004"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "5-methoxy-N,N-dimethyltryptamine",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:00:00.000005"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "S 3304",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:00:00.000006"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "Sodium phosphate, dibasic",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:00:00.000007"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "Levobetaxolol",
      "classification": "EXPERIMENTAL",
      "timestamp": "2026-01-20T00:00:00.000008"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "Enalaprilat",
      "classification": "CONFIRMED",
      "timestamp": "2026-01-20T00:00:00.000009"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "5'-Cytidylic acid, 2',3'-dideoxy-",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:00:00.000010"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "Tegobuvir",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:36:23.443265"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "Camicinal",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:36:23.443265"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:36:23.443265"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "Soybean oil",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:36:23.443265"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "SO-101",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:36:23.443265"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "(3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:36:23.443265"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "Temocapril",
      "classification": "EXPERIMENTAL",
      "timestamp": "2026-01-19T23:36:23.443265"
    },
    {
      "disease": "Atrial fibrillation",
      "drug": "Lasmiditan",
      "classification": "NOVEL",
      "timestamp": "2026-01-19T23:36:23.443265"
    },
    {
      "disease": "Psoriasis",
      "drug": "Daclizumab",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:03:57.860730",
      "evidence": "FDA approved for MS/transplant rejection. Psoriasis was a SIDE EFFECT, not treatment. Withdrawn 2018."
    },
    {
      "disease": "Psoriasis",
      "drug": "Adecatumumab",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:03:57.860730",
      "evidence": "Anti-EpCAM antibody for cancer (breast, prostate, colorectal). No psoriasis connection."
    },
    {
      "disease": "Psoriasis",
      "drug": "Dalotuzumab",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:03:57.860730",
      "evidence": "Anti-IGF-1R antibody for cancer. No psoriasis trials."
    },
    {
      "disease": "Psoriasis",
      "drug": "Tositumomab",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:03:57.860730",
      "evidence": "Anti-CD20 antibody for NHL. CD20 antibodies can INDUCE psoriasis, not treat it."
    },
    {
      "disease": "Psoriasis",
      "drug": "Natalizumab",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:03:57.860730",
      "evidence": "FDA approved for MS and Crohn's disease only. Not indicated for psoriasis."
    },
    {
      "disease": "Psoriasis",
      "drug": "Concizumab",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:03:57.860730",
      "evidence": "Anti-TFPI antibody for hemophilia. TFPI alterations observed in psoriasis (biomarker), not a treatment."
    },
    {
      "disease": "Psoriasis",
      "drug": "Lintuzumab",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:03:57.860730",
      "evidence": "Anti-CD33 antibody for AML/leukemia. No psoriasis connection."
    },
    {
      "disease": "Psoriasis",
      "drug": "Equol",
      "classification": "EXPERIMENTAL",
      "timestamp": "2026-01-20T00:03:57.860730",
      "evidence": "Soy isoflavone metabolite. Preclinical anti-psoriatic effects in mice (genistein cream, IMQ model). No Phase I+ human trials for psoriasis. Source: PMC10299547, Nature Sci Rep s41598-018-24726-z"
    },
    {
      "disease": "Psoriasis",
      "drug": "example 114 [US8530652]",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:03:57.860730",
      "evidence": "Patent compound - PAK4 kinase inhibitor (pyrrolopyrazole). No clinical evidence for psoriasis."
    },
    {
      "disease": "Psoriasis",
      "drug": "Rozrolimupab",
      "classification": "NOVEL",
      "timestamp": "2026-01-20T00:03:57.860730",
      "evidence": "Anti-RhD antibody mixture for ITP. No psoriasis connection."
    },
    {
      "disease": "Type 2 diabetes",
      "timestamp": "2026-01-20T00:08:46.504721",
      "drugs_researched": 24,
      "confirmed": 7,
      "novel": 17,
      "experimental": 0
    },
    {
      "timestamp": "2026-01-20T05:21:18.961630",
      "session": "type_2_diabetes_continued",
      "drugs_researched": 6,
      "results": {
        "confirmed": 0,
        "experimental": 0,
        "novel": 6
      },
      "notes": "Researched positions 2-7 from Type 2 diabetes candidates. Hit 5+ consecutive NOVEL threshold (actually 6 consecutive)."
    },
    {
      "timestamp": "2026-01-20T05:23:15.037147",
      "session": "obesity_initial",
      "drugs_researched": 10,
      "results": {
        "confirmed": 0,
        "experimental": 1,
        "novel": 9
      },
      "notes": "Researched first 10 obesity candidates. 1 EXPERIMENTAL (Piromelatine - preclinical metabolic benefits), 9 NOVEL. High novel rate expected for obesity given limited approved treatments."
    },
    {
      "timestamp": "2026-01-20T05:24:27.215147",
      "session": "obesity_continued",
      "drugs_researched": 10,
      "results": {
        "confirmed": 0,
        "experimental": 0,
        "novel": 10
      },
      "notes": "Researched positions 11-20 for Obesity. All 10 classified as NOVEL. Total: 10 consecutive NOVEL (exceeds threshold of 5)."
    },
    {
      "timestamp": "2026-01-20T05:28:19.441732",
      "session": "asthma_initial",
      "drugs_researched": 15,
      "results": {
        "confirmed": 1,
        "experimental": 4,
        "novel": 10
      },
      "notes": "Researched first 15 asthma candidates. 1 CONFIRMED (Gefapixant - FDA approved for chronic cough), 4 EXPERIMENTAL (nitrite, prinomastat, zopolrestat, TUDCA), 10 NOVEL. Multiple promising experimental candidates with preclinical/Phase data."
    },
    {
      "timestamp": "2026-01-20T05:29:49.293515",
      "session": "asthma_batch2",
      "drugs_researched": 10,
      "results": {
        "confirmed": 0,
        "experimental": 2,
        "novel": 8
      },
      "notes": "Researched positions 16-25 for Asthma. 2 EXPERIMENTAL (MK-0873 - PDE4 inhibitor with preclinical asthma data, Puerarin - TCM isoflavone with rodent model efficacy), 8 NOVEL. Total: 25 drugs researched, 1 confirmed, 6 experimental."
    },
    {
      "timestamp": "2026-01-20T05:30:58.588947",
      "session": "asthma_batch3_final",
      "drugs_researched": 3,
      "results": {
        "confirmed": 0,
        "experimental": 1,
        "novel": 2
      },
      "notes": "Completed Asthma research: final 3 drugs (positions 28-30). 1 EXPERIMENTAL (5-Bromoindirubin - GSK-3\u03b2 inhibitor class with preclinical asthma data), 2 NOVEL. TOTAL ASTHMA: 30 drugs, 1 CONFIRMED, 7 EXPERIMENTAL, 22 NOVEL. Max candidates reached."
    },
    {
      "timestamp": "2026-01-20T05:32:16.350154",
      "session": "copd_batch1",
      "drugs_researched": 10,
      "results": {
        "confirmed": 4,
        "experimental": 0,
        "novel": 6
      },
      "notes": "Researched first 10 COPD candidates. 4 CONFIRMED (Arformoterol, Formoterol, Prednisolone, Indacaterol - all FDA approved COPD treatments), 6 NOVEL. Strong start with multiple approved bronchodilators."
    },
    {
      "timestamp": "2026-01-20T05:32:59.267539",
      "session": "copd_batch2",
      "drugs_researched": 15,
      "results": {
        "confirmed": 0,
        "experimental": 0,
        "novel": 15
      },
      "notes": "Researched COPD drugs 11-25. All 15 classified as NOVEL (anticholinergics, GI drugs, diuretics, etc. - no COPD connection)."
    },
    {
      "timestamp": "2026-01-20T05:33:44.528417",
      "session": "copd_batch3_final",
      "drugs_researched": 5,
      "results": {
        "confirmed": 1,
        "experimental": 2,
        "novel": 2
      },
      "notes": "Completed COPD research: final 5 drugs (26-30). 1 CONFIRMED (Doxofylline - methylxanthine bronchodilator), 2 EXPERIMENTAL (Azithromycin - chronic macrolide for exacerbation prevention, Doxapram - acute respiratory stimulant). TOTAL COPD: 30 drugs, 5 CONFIRMED, 2 EXPERIMENTAL, 23 NOVEL. Max candidates reached."
    }
  ]
}